

FORM PTO-1390
(REV. 11-2000)

U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE

ATTORNEY'S DOCKET NUMBER

TRANSMITTAL LETTER TO THE UNITED STATES
DESIGNATED/ELECTED OFFICE (DO/EO/US)
CONCERNING A FILING UNDER 35 U.S.C. 371

13254-00012

U.S. APPLICATION NO. (If known, see 37 CFR 1.5)

09/868196

INTERNATIONAL APPLICATION NO.

INTERNATIONAL FILING DATE

PRIORITY DATE CLAIMED

PCT/US99/29795

15 December 1999 (15.12.99)

15 December 1998 (15.12.98)

TITLE OF INVENTION hCG Therapy for Treatment of Breast Cancer

APPLICANT(S) FOR DO/EO/US RUSSO, Irma H.; RUSSO, Jose; DELUCA, Giampiero and JANSSENS, Jaak

Applicant herewith submits to the United States Designated/Elected Office (DO/EO/US) the following items and other information:

1. ☒ This is a **FIRST** submission of items concerning a filing under 35 U.S.C. 371.
2. ☐ This is a **SECOND** or **SUBSEQUENT** submission of items concerning a filing under 35 U.S.C. 371.
3. ☐ This is an express request to begin national examination procedures (35 U.S.C. 371(f)). The submission must include items (5), (6), (9) and (21) indicated below.
4. ☐ The US has been elected by the expiration of 19 months from the priority date (Article 31).
5. ☒ A copy of the International Application as filed (35 U.S.C. 371(c)(2))
 - a. ☐ is attached hereto (required only if not communicated by the International Bureau).
 - b. ☒ has been communicated by the International Bureau.
 - c. ☐ is not required, as the application was filed in the United States Receiving Office (RO/US).
6. ☐ An English language translation of the International Application as filed (35 U.S.C. 371(c)(2)).
 - a. ☐ is attached hereto.
 - b. ☐ has been previously submitted under 35 U.S.C. 154(d)(4).
7. ☒ Amendments to the claims of the International Application under PCT Article 19 (35 U.S.C. 371(c)(3))
 - a. ☐ are attached hereto (required only if not communicated by the International Bureau).
 - b. ☐ have been communicated by the International Bureau.
 - c. ☐ have not been made; however, the time limit for making such amendments has NOT expired.
 - d. ☒ have not been made and will not be made.
8. ☐ An English language translation of the amendments to the claims under PCT Article 19 (35 U.S.C. 371(c)(3)).
9. ☐ An oath or declaration of the inventor(s) (35 U.S.C. 371(c)(4)).
10. ☐ An English language translation of the annexes of the International Preliminary Examination Report under PCT Article 36 (35 U.S.C. 371(c)(5)).

Items 11 to 20 below concern document(s) or information included:

11. ☐ An Information Disclosure Statement under 37 CFR 1.97 and 1.98.
12. ☐ An assignment document for recording. A separate cover sheet in compliance with 37 CFR 3.28 and 3.31 is included.
13. ☒ A **FIRST** preliminary amendment.
14. ☐ A **SECOND** or **SUBSEQUENT** preliminary amendment.
15. ☐ A substitute specification.
16. ☐ A change of power of attorney and/or address letter.
17. ☐ A computer-readable form of the sequence listing in accordance with PCT Rule 13ter.2 and 35 U.S.C. 1.821 - 1.825.
18. ☐ A second copy of the published international application under 35 U.S.C. 154(d)(4).
19. ☐ A second copy of the English language translation of the international application under 35 U.S.C. 154(d)(4).
20. ☐ Other items or information:

14 JUN 2001

U.S. APPLICATION NO. (if known, see 37 CFR 1.5)

09/868196

INTERNATIONAL APPLICATION NO
PCT/US99/29795

ATTORNEY'S DOCKET NUMBER
13254-00012

21. ☒ The following fees are submitted:

BASIC NATIONAL FEE (37 CFR 1.492 (a) (1) - (5)):

Neither international preliminary examination fee (37 CFR 1.482)
nor international search fee (37 CFR 1.445(a)(2)) paid to USPTO
and International Search Report not prepared by the EPO or JPO \$1000.00

International preliminary examination fee (37 CFR 1.482) not paid to
USPTO but International Search Report prepared by the EPO or JPO \$860.00

International preliminary examination fee (37 CFR 1.482) not paid to USPTO
but international search fee (37 CFR 1.445(a)(2)) paid to USPTO \$710.00

International preliminary examination fee (37 CFR 1.482) paid to USPTO
but all claims did not satisfy provisions of PCT Article 33(1)-(4) \$690.00

International preliminary examination fee (37 CFR 1.482) paid to USPTO
and all claims satisfied provisions of PCT Article 33(1)-(4) \$100.00

ENTER APPROPRIATE BASIC FEE AMOUNT =

CALCULATIONS PTO USE ONLY

\$ 860.00

\$ 130.00

Surcharge of \$130.00 for furnishing the oath or declaration later than ☐ 20 ☒ 30
months from the earliest claimed priority date (37 CFR 1.492(e)).

CLAIMS	NUMBER FILED	NUMBER EXTRA	RATE	\$
Total claims	103 -20 =	83	x \$18.00	\$ 1,494.00
Independent claims	7 -3 =	4	x \$80.00	\$ 320.00
MULTIPLE DEPENDENT CLAIM(S) (if applicable)			+ \$270.00	\$ 0.00

TOTAL OF ABOVE CALCULATIONS = \$ 2,804.00

☐ Applicant claims small entity status. See 37 CFR 1.27. The fees indicated above
are reduced by 1/2. + \$ 0.00

SUBTOTAL = \$ 2,804.00

Processing fee of \$130.00 for furnishing the English translation later than ☐ 20 ☐ 30
months from the earliest claimed priority date (37 CFR 1.492(f)). \$

TOTAL NATIONAL FEE = \$ 2,804.00

Fee for recording the enclosed assignment (37 CFR 1.21(h)). The assignment must be
accompanied by an appropriate cover sheet (37 CFR 3.28, 3.31). \$40.00 per property + \$ 0.00

TOTAL FEES ENCLOSED = \$ 2,804.00

Amount to be
refunded: \$

charged: \$

a. ☒ A check in the amount of \$ 2,804.00 to cover the above fees is enclosed.

b. ☐ Please charge my Deposit Account No. _____ in the amount of \$ _____ to cover the above fees.
A duplicate copy of this sheet is enclosed.

c. ☒ The Commissioner is hereby authorized to charge any additional fees which may be required, or credit any
overpayment to Deposit Account No. 50-1089. A duplicate copy of this sheet is enclosed.

d. ☐ Fees are to be charged to a credit card. **WARNING:** Information on this form may become public. **Credit card
information should not be included on this form.** Provide credit card information and authorization on PTO-2038.

NOTE: Where an appropriate time limit under 37 CFR 1.494 or 1.495 has not been met, a petition to revive (37 CFR
1.137 (a) or (b)) must be filed and granted to restore the application to pending status.

SEND ALL CORRESPONDENCE TO:

Janet E. REED
Saul Ewing
1500 Market Street, 38th Floor
Centre Square West
Philadelphia, PA 19102
US

SIGNATURE

Janet E. REED
NAME

36,252
REGISTRATION NUMBER

§371 US National
PCT US99/29795

FCCC 99-01/13254.00006
Russo et al.

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re the Application of)
)
Irma Russo et al.)
)
Application No. [Not Yet Assigned])
35 U.S.C. §371 filing of US99/29795)
)
Filed: Herewith)
)
For: hCG Therapy for Treatment of)
Breast Cancer)

PRELIMINARY AMENDMENT

Please amend the above-identified application as follows:

In the claims:

1. (Amended) A method of making a medicament for treatment of mammary tumors, comprising incorporating hCG into the medicament in an amount effective to treat the mammary tumors.
2. (Amended) The method of claim 1, wherein the medicament is for the treatment of clinically manifest mammary tumors.
3. (Amended) The method of claim 2, wherein the clinically manifest mammary tumor is a primary tumor.
4. (Amended) The method of claim 1, wherein the tumor is a non-invasive carcinoma.

5. (Amended) The method of claim 4, wherein the tumor is ductal carcinoma *in situ* or lobular carcinoma *in situ*.
6. (Amended) The method of claim 1, wherein the tumor is an invasive carcinoma.
7. (Amended) The method of claim 6, wherein the tumor is tubular or lobular invasive carcinoma.
8. (Amended) The method of claim 2, wherein the clinically manifest mammary tumor is a metastatic mammary tumor.
9. (Amended) The method of claim 1, wherein the medicament is for the treatment or prevention of mammary tumors in premenopausal or postmenopausal women.
10. (Amended) The method of claim 1, wherein the medicament is used in combination with at least one other cancer therapy.
11. (Amended) The method of claim 10, wherein the other cancer therapy is surgery or chemotherapy.
12. (Amended) The method of claim 1, wherein the mammary tumors comprise cells that are estrogen receptor-positive.
13. (Amended) The method of claim 12, wherein the medicament is used in combination with an antiestrogen.
14. (Amended) The method of claim 13, wherein the medicament is used simultaneously, sequentially or separately with the antiestrogen.

15. (Amended) The method of claim 13, wherein the antiestrogen is Tamoxifen.

16. (Amended) The method of claim 15, wherein Tamoxifen is administered orally in a daily amount of about 30 milligrams.

17. (Amended) The method of claim 1, wherein the medicament comprises an amount of hCG that enables administration of 100 to 20,000 IU of hCG to a patient per day.

18. (Amended) The method of claim 1, wherein the medicament comprises an amount of hCG that enables administration of 50 to 50,000 micrograms of hCG to a patient per day.

19. (Amended) The method of claim 18, wherein hCG is administered in an amount of 250 to 3,000 micrograms per day.

20. (Amended) The method of claim 1, wherein the medicament is formulated to enable administration thereof every second day.

21. (Amended) The method of claim 1, wherein the medicament is formulated to enable administration thereof three times a week.

22. (Amended) The method of claim 1, wherein the medicament is formulated to enable administration thereof for several weeks.

23. (Amended) The method of claim 22, wherein the medicament is administered for at least 12 weeks.

24. (Amended) The method of claim 1, wherein the medicament is formulated for subcutaneous administration.

25. (Amended) The method of claim 13, wherein the medicament is used in combination with Type 1 interferon and the antiestrogen.

26. (Amended) The method of claim 1, wherein the hCG is recombinant hCG.

27. (Amended) The method of claim 1, wherein the hCG is replaced by a protein having the biological activity of hCG or a binding activity toward a hCG receptor.

28. (Amended) The method of claim 27, wherein the protein is selected from the group consisting of LH, recombinant LH, LH fusion molecule, TSH fusion molecules and FSH fusion molecules.

30. (Amended) The pharmaceutical composition of claim 29, formulated for administration of the hCG in an amount of 100 to 20,000 IU to a patient per day.

31. (Amended) The pharmaceutical composition of claim 29, formulated for administration of the hCG in an amount of 50 to 50,000 micrograms to a patient per day.

32. (Amended) The pharmaceutical composition of claim 31, wherein the hCG is administered in an amount of 250 to 3,000 micrograms per day.

33. (Amended) The pharmaceutical composition of claim 29, formulated for administration every second day.

34. (Amended) The pharmaceutical composition of claim 29, formulated for administration three times a week.

35. (Amended) The pharmaceutical composition of claim 29, formulated for administration for several weeks.

36. (Amended) The pharmaceutical composition of claim 29, formulated for administration for at least 12 weeks.

37. (Amended) The pharmaceutical composition of claim 29, formulated for subcutaneous administration.

38. (Amended) The pharmaceutical composition of claim 29, which is used simultaneously, sequentially or separately with an antiestrogen.

41. (Amended) The pharmaceutical composition of claim 38, which is used in combination with a Type 1 interferon.

42. (Amended) The pharmaceutical composition of claim 29, wherein hCG is recombinant hCG.

43. (Amended) The pharmaceutical composition of claim 29, wherein hCG is replaced by a protein having the biological activity of hCG and/or a binding activity toward the hCG receptor.

45. (Amended) A method of treating or preventing mammary tumors, comprising administering a host in need thereof an amount of hCG effective to inhibit proliferation of mammary tumor cells.

Cancel claims 46-52.

53. (Amended) An article of manufacture comprising a container, in which is contained a pharmaceutical composition according to claim 29, and which comprises a label stating the use of the pharmaceutical composition for the treatment of breast cancer.

Add the following new claims:

54. (New) The method of claim 45, wherein the mammary tumor is a clinically manifest mammary tumor.

55. (New) The method of claim 54, wherein the clinically manifest mammary tumor is a primary tumor.

56. (New) The method of claim 45, wherein the mammary tumor is a non-invasive carcinoma.

57. (New) The method of claim 56, wherein the carcinoma is ductal carcinoma *in situ* or lobular carcinoma *in situ*.

58. (New) The method of claim 45, wherein the mammary tumor is an invasive carcinoma.

59. (New) The method of claim 58, wherein the carcinoma is tubular or lobular invasive carcinoma.

60. (New) The method of claim 54, wherein the clinically manifest mammary tumor is a metastatic mammary tumor.

61. (New) The method of claim 45, wherein the host is a premenopausal woman.

62. (New) The method of claim 45, wherein the host is a postmenopausal woman.

63. (New) The method of claim 45, combined with at least one other cancer therapy.

64. (New) The method of claim 63, wherein the at least one other cancer therapy is surgery or chemotherapy.

65. (New) The method of claim 45, wherein the mammary tumors comprise cells that are estrogen receptor-positive.

66. (New) The method of claim 64, wherein the hCG is administered in combination with an antiestrogen.

67. (New) The method of claim 66, wherein the hCG is administered simultaneously, sequentially or separately with the antiestrogen.

68. (New) The method of claim 66, wherein the antiestrogen is Tamoxifen.

69. (New) The method of claim 68, wherein the Tamoxifen is administered orally in a daily amount of about 30 milligrams.

70. (New) The method of claim 45, wherein the hCG is administered in an amount of 100 to 20,000 IU per day.

71. (New) The method of claim 45, wherein the hCG is administered in amount of 50 to 50,000 micrograms per day.

72. (New) The method of claim 71, wherein the hCG is administered in an amount of 250 to 3,000 micrograms per day.

73. (New) The method of claim 45, wherein the hCG is administered every second day.

74. (New) The method of claim 45, wherein the hCG is administered three times each week.

75. (New) The method of claim 45, wherein the hCG is administered for several weeks.

76. (New) The method of claim 75, wherein the hCG is administered for at least 12 weeks.

77. (New) The method of claim 45, wherein the hCG is administered subcutaneously.

78. (New) The method of claim 45, wherein the hCG is administered in combination with Type 1 interferon.

79. The method of claim 78, wherein the hCG and Type 1 interferon are administered in combination with an antiestrogen.

80. (New) The method of claim 45, wherein the hCG is recombinant hCG.

81. (New) The method of claim 45, wherein the hCG is replaced by a protein having the biological activity of hCG or a binding activity toward a hCG receptor.

82. (New) The method of claim 81, wherein the protein is selected from the group consisting of LH, recombinant LH, LH fusion molecule, TSH fusion molecules and FSH fusion molecules.

83. (New) A pharmaceutical composition for the treatment of breast cancer comprising a pharmaceutically active amount of hCG and a pharmaceutically active amount of an antiestrogen, in the presence of one or more pharmaceutically acceptable excipients.

84. (New) The pharmaceutical composition of claim 83, formulated for administration of the hCG to a patient in an amount of 100 to 20,000 IU per day.

85. (New) The pharmaceutical composition of claim 83, formulated for administration of the hCG to a patient in an amount of 50 to 50,000 micrograms per day.

86. (New) The pharmaceutical composition of 85, wherein the hCG is administered to the patient in an amount of 250 to 3,000 micrograms per day.

87. (New) The pharmaceutical composition of claim 83, wherein the hCG is recombinant hCG.

88. (New) The pharmaceutical composition of claim 83, wherein the antiestrogen is Tamoxifen.

89. (New) The pharmaceutical composition of claim 83, formulated for use in combination with a Type 1 interferon.

90. (New) The pharmaceutical composition of claim 83, formulated for subcutaneous administration.

91. (New) An article of manufacture comprising a container, in which is contained:

- a) the pharmaceutical composition of claim 29; and
- b) an antiestrogen;

and which comprises a label stating the use of the pharmaceutical composition and the antiestrogen, together or separately, for the treatment of breast cancer.

92. (New) The article of manufacture of claim 91, wherein the antiestrogen is Tamoxifen.

93. (New) The article of manufacture of claim 92, wherein the Tamoxifen formulated for oral administration in a daily amount of about 30 milligrams.

94. The article of manufacture of claim 91, which further comprises a Type 1 interferon, wherein the label further states the use of the pharmaceutical composition, the antiestrogen and the Type 1 interferon, together or separately, for the treatment of breast cancer.

95. (New) A method of treating or preventing mammary tumors, wherein the tumors comprise cells that are estrogen receptor-positive, the method comprising administering a host in need thereof an amount of hCG effective to inhibit proliferation of mammary tumor cells, wherein the hCG is administered in combination with an antiestrogen.

96. (New) The method of claim 95, wherein the hCG is administered simultaneously, sequentially or separately with the antiestrogen.

97. (New) The method of claim 95, wherein the antiestrogen is Tamoxifen.

98. (New) The method of claim 97, wherein the Tamoxifen is administered orally in a daily amount of about 30 milligrams.

99. (New) The method of claim 95, wherein the hCG is administered in amount of 50 to 50,000 micrograms per day.

100. (New) The method of claim 95, wherein the hCG is administered every second day or three times each week.

101. (New) The method of claim 95, wherein the hCG is administered for several weeks.

102. (New) The method of claim 95, wherein the hCG is administered subcutaneously.

103. (New) The method of claim 95, wherein the hCG and antiestrogen are administered in combination with Type 1 interferon.

REMARKS


Claims 1-53 were pending in the present application. Claims 46-52 were canceled in this Preliminary Amendment. Claims 1-28, 30-38, 41-43 and 45 were amended in order to format the claims for prosecution in the U.S. Patent and Trademark Office, and to correct occasional typographical errors. These amendments address formalities and do not affect patentability of the subject matter of any claim or alter the scope of the claims in any way.

New claims 54-103 were added in order to more fully define the subject matter Applicants regard as their invention. No new matter has been added.

Respectfully Submitted,

Saul Ewing, L.L.P.

By:


Janet E. Reed, Ph.D.
Registration No. 36,252

Telephone: (215) 972-8386
Facsimile: (215) 972-2292

Marked-up Version Showing Changes Made:
(unchanged claims shown in small type)

1. (Amended) A method of making [Use of hCG for the manufacture of] a medicament for treatment of mammary tumors, comprising incorporating hCG into the medicament in an amount effective to treat the mammary tumors.
2. (Amended) The method of claim 1, wherein the medicament is [Use of hCG according to claim 1, for the manufacture of a medicament] for the treatment of clinically manifest mammary tumors.
3. (Amended) The method of [Use according to] claim 2, wherein the clinically manifest mammary tumor is a primary tumor.
4. (Amended) The method of claim 1, [Use according to any of the preceding claims,] wherein the tumor is a non-invasive carcinoma.
5. (Amended) The method of [Use according to] claim 4, wherein the tumor is ductal carcinoma *in situ* or lobular carcinoma *in situ*.
6. (Amended) The method of claim 1, [Use according to any of claims 1 to 3,] wherein the tumor is an invasive carcinoma.
7. (Amended) The method of [Use according to] claim 6, wherein the tumor is tubular or lobular invasive carcinoma.

8. (Amended) The method of [Use according to] claim 2, wherein the clinically manifest mammary tumor is a metastatic mammary tumor.

9. (Amended) The method of claim 1, wherein the medicament is [Use of hCG for the manufacture of a medicament] for the treatment [and/]or prevention of mammary tumors in premenopausal or postmenopausal women.

10. (Amended) The method of claim 1, wherein the medicament [Use according to any of the preceding claims, wherein hCG] is used [as an adjuvant] in combination with at least one other cancer therapy.

11. (Amended) The method of [Use according to] claim 10, wherein the other cancer therapy is surgery or chemotherapy.

12. (Amended) The method of claim 1 [Use according to any of the preceding claims], wherein the mammary tumors comprise [treated tumor] cells that are estrogen receptor-positive.

13. (Amended) The method of [Use according to] claim 12, wherein the medicament [hCG] is used in combination with an antiestrogen.

14. (Amended) The method of claim [Use according to] claim 13 , wherein the medicament [in which hCG] is used simultaneously, sequentially or separately with the antiestrogen.

15. (Amended) The method of claim 13 [Use according to claims 13 or 14], wherein the antiestrogen is Tamoxifen.

16. (Amended) The method of [Use according to] claim 15, wherein Tamoxifen is administered orally in a daily amount of about 30 milligrams.

17. (Amended) The method of claim 1, wherein the medicament comprises an amount of hCG that enables administration [Use according to any of the preceding claims, wherein hCG is administered in an amount] of 100 to 20,000 IU of hCG to a [per] patient per day.

18. (Amended) The method of claim 1, wherein the medicament comprises an amount of hCG that enables administration [Use according to any of the preceding claims, wherein hCG is administered in amount] of 50 to 50,000 micrograms of hCG to a [per] patient per day.

19. (Amended) The method of [Use according to] claim 18, wherein hCG is administered in an amount of 250 to 3,000 micrograms [per patient] per day.

20. (Amended) The method of claim 1, wherein the medicament is formulated to enable administration thereof [Use according to any of the preceding claims, wherein hCG is administered] every second day.

21. (Amended) The method of claim 1, wherein the medicament is formulated to enable administration thereof [Use according to any of the preceding claims, wherein hCG is administered] three times a week.

22. (Amended) The method of claim 1, wherein the medicament is formulated to enable administration thereof [Use according to any of the preceding claims, wherein hCG is administered] for several weeks.

23. (Amended) The method of [Use according to] claim 22, wherein the medicament

[hCG] is administered for at least 12 weeks.

24. (Amended) The method of claim 1, wherein the medicament is formulated for subcutaneous administration [Use according to any of the preceding claims, wherein hCG is administered subcutaneously].

25. (Amended) The method of claim 13, wherein the medicament is used in combination with [Use according to any of the preceding claims, further comprising the use of] Type 1 interferon and the [in combination with hCG and] antiestrogen.

26. (Amended) The method of claim 1, [Use according to any of the preceding claims], wherein the hCG is recombinant hCG.

27. (Amended) The method of claim 1 [Use according to any of claims 1 to 25], wherein the hCG is replaced by a protein having the biological activity of hCG [and/]or a binding activity toward a [the] hCG receptor.

28. (Amended) The method of [Use according to] claim 27, wherein the protein is selected from the group consisting of LH, recombinant LH, LH fusion molecule, TSH fusion molecules and FSH fusion molecules.

29. (Not changed) A pharmaceutical composition comprising a pharmaceutically active amount of hCG, in the presence of one or more pharmaceutically acceptable excipients, for the treatment of breast cancer.

30. (Amended) The pharmaceutical composition of claim 29, formulated for administration of the hCG [wherein hCG is administered] in an amount of 100 to 20,000 IU to a [per] patient per day.

31. (Amended) The pharmaceutical composition of claim 29 [or 30], formulated for administration of the hCG [wherein hCG is administered] in an amount of 50 to 50,000 micrograms to a [per] patient per day.

32. (Amended) The pharmaceutical composition of claim 31 [any of claims 29-31], wherein the hCG is administered in an amount of 250 to 3,000 micrograms [per patient] per day.

33. (Amended) The pharmaceutical composition of claim 29 [any of claims 29 to 32], formulated for administration [wherein hCG is administered] every second day.

34. (Amended) The pharmaceutical composition of claim 29 [any of claims 29 to 32], formulated for administration [wherein hCG is administered] three times a week.

35. (Amended) The pharmaceutical composition of claim 29 [any of claims 29 to 34], formulated for administration [wherein hCG is administered] for several weeks.

36. (Amended) The pharmaceutical composition of claim 29 [any of claims 29 to 35], formulated for administration [wherein hCG is administered] for at least 12 weeks.

37. (Amended) The pharmaceutical composition of claim 29 [any of claims 29 to 36], formulated for subcutaneous administration [wherein hCG is administered subcutaneously].

38. (Amended) The pharmaceutical composition of claim 29 [any of claims 29 to 37], which is used simultaneously, sequentially or separately with an antiestrogen.

39. (No change) The pharmaceutical composition of claim 38, wherein the antiestrogen is Tamoxifen.

40. (No change) The pharmaceutical composition of claim 39, wherein Tamoxifen is administered orally in a daily amount of about 30 milligrams.

41. (Amended) The pharmaceutical composition of claim 38 [any of claims 38 to 40], which is used in combination with a Type 1 interferon.

42. (Amended) The pharmaceutical composition of claim 29 [any of claims 29 to 41], wherein hCG is recombinant hCG.

43. (Amended) The pharmaceutical composition of claim 29 [any of claims 29 to 41], wherein hCG is replaced by a protein having the biological activity of hCG and/or a binding activity toward the hCG receptor.

44. (No change) The pharmaceutical composition of claim 43, wherein the protein is selected from the group consisting of LH, recombinant LH, LH fusion molecules, FSH fusion molecules and TSH fusion molecules.

45. (Amended) A method of treating or preventing mammary tumors [inhibiting the proliferation of breast cancer cells, comprising administering a host in need thereof an [effective inhibiting] amount of hCG effective to inhibit proliferation of mammary tumor cells].

Cancel claims 46-52.

53. (Amended) An article of manufacture comprising a container, in which is contained a pharmaceutical composition according to claim 29 [any of claims 29 to 44], and which comprises a label stating the use of the pharmaceutical composition for the treatment of breast cancer.

Add the following new claims:

54. (New) The method of claim 45, wherein the mammary tumor is a clinically manifest mammary tumor.

55. (New) The method of claim 54, wherein the clinically manifest mammary tumor is a primary tumor.

56. (New) The method of claim 45, wherein the mammary tumor is a non-invasive carcinoma.

57. (New) The method of claim 56, wherein the carcinoma is ductal carcinoma *in situ* or lobular carcinoma *in situ*.

58. (New) The method of claim 45, wherein the mammary tumor is an invasive carcinoma.

59. (New) The method of claim 58, wherein the carcinoma is tubular or lobular invasive carcinoma.

60. (New) The method of claim 54, wherein the clinically manifest mammary tumor is a metastatic mammary tumor.

61. (New) The method of claim 45, wherein the host is a premenopausal woman.

62. (New) The method of claim 45, wherein the host is a postmenopausal woman.

63. (New) The method of claim 45, combined with at least one other cancer therapy.

64. (New) The method of claim 63, wherein the at least one other cancer therapy is surgery or chemotherapy.

65. (New) The method of claim 45, wherein the mammary tumors comprise cells that are estrogen receptor-positive.

66. (New) The method of claim 64, wherein the hCG is administered in combination with an antiestrogen.

67. (New) The method of claim 66, wherein the hCG is administered simultaneously, sequentially or separately with the antiestrogen.

68. (New) The method of claim 66, wherein the antiestrogen is Tamoxifen.

69. (New) The method of claim 68, wherein the Tamoxifen is administered orally in a daily amount of about 30 milligrams.

70. (New) The method of claim 45, wherein the hCG is administered in an amount of 100 to 20,000 IU per day.

71. (New) The method of claim 45, wherein the hCG is administered in amount of 50 to 50,000 micrograms per day.

72. (New) The method of claim 71, wherein the hCG is administered in an amount of 250 to 3,000 micrograms per day.

73. (New) The method of claim 45, wherein the hCG is administered every second day.

74. (New) The method of claim 45, wherein the hCG is administered three times each week.

75. (New) The method of claim 45, wherein the hCG is administered for several weeks.

76. (New) The method of claim 75, wherein the hCG is administered for at least 12 weeks.

77. (New) The method of claim 45, wherein the hCG is administered subcutaneously.

78. (New) The method of claim 45, wherein the hCG is administered in combination with Type 1 interferon.

79. The method of claim 78, wherein the hCG and Type 1 interferon are administered in combination with an antiestrogen.

80. (New) The method of claim 45, wherein the hCG is recombinant hCG.

81. (New) The method of claim 45, wherein the hCG is replaced by a protein having the biological activity of hCG or a binding activity toward a hCG receptor.

82. (New) The method of claim 81, wherein the protein is selected from the group consisting of LH, recombinant LH, LH fusion molecule, TSH fusion molecules and FSH fusion molecules.

83. (New) A pharmaceutical composition for the treatment of breast cancer comprising a pharmaceutically active amount of hCG and a pharmaceutically active amount of an antiestrogen,

in the presence of one or more pharmaceutically acceptable excipients.

84. (New) The pharmaceutical composition of claim 83, formulated for administration of the hCG to a patient in an amount of 100 to 20,000 IU per day.

85. (New) The pharmaceutical composition of claim 83, formulated for administration of the hCG to a patient in an amount of 50 to 50,000 micrograms per day.

86. (New) The pharmaceutical composition of 85, wherein the hCG is administered to the patient in an amount of 250 to 3,000 micrograms per day.

87. (New) The pharmaceutical composition of claim 83, wherein the hCG is recombinant hCG.

88. (New) The pharmaceutical composition of claim 83, wherein the antiestrogen is Tamoxifen.

89. (New) The pharmaceutical composition of claim 83, formulated for use in combination with a Type 1 interferon.

90. (New) The pharmaceutical composition of claim 83, formulated for subcutaneous administration.

91. (New) An article of manufacture comprising a container, in which is contained:

a) the pharmaceutical composition of claim 29; and

b) an antiestrogen;

and which comprises a label stating the use of the pharmaceutical composition and the

antiestrogen, together or separately, for the treatment of breast cancer.

92. (New) The article of manufacture of claim 91, wherein the antiestrogen is Tamoxifen.

93. (New) The article of manufacture of claim 92, wherein the Tamoxifen formulated for oral administration in a daily amount of about 30 milligrams.

94. The article of manufacture of claim 91, which further comprises a Type 1 interferon, wherein the label further states the use of the pharmaceutical composition, the antiestrogen and the Type 1 interferon, together or separately, for the treatment of breast cancer.

95. (New) A method of treating or preventing mammary tumors, wherein the tumors comprise cells that are estrogen receptor-positive, the method comprising administering a host in need thereof an amount of hCG effective to inhibit proliferation of mammary tumor cells, wherein the hCG is administered in combination with an antiestrogen.

96. (New) The method of claim 95, wherein the hCG is administered simultaneously, sequentially or separately with the antiestrogen.

97. (New) The method of claim 95, wherein the antiestrogen is Tamoxifen.

98. (New) The method of claim 97, wherein the Tamoxifen is administered orally in a daily amount of about 30 milligrams.

99. (New) The method of claim 95, wherein the hCG is administered in amount of 50 to 50,000 micrograms per day.

100. (New) The method of claim 95, wherein the hCG is administered every second day or three times each week.

101. (New) The method of claim 95, wherein the hCG is administered for several weeks.

102. (New) The method of claim 95, wherein the hCG is administered subcutaneously.

103. (New) The method of claim 95, wherein the hCG and antiestrogen are administered in combination with Type 1 interferon.

hCG THERAPY FOR THE TREATMENT OF BREAST CANCER

This application claims priority to European Application No. 98123817.3, filed December 15, 1998, the entirety of which is incorporated by reference herein.

5 FIELD OF THE INVENTION

This invention relates to the field of cancer therapy. More particularly, the invention relates to the prevention or treatment of clinically manifest mammary tumor (breast cancer) and metastatic mammary tumor by
10 administration of human Chorionic Gonadotropin (hCG). The treatment of mammary tumor in postmenopausal women is also contemplated. The treatment preferably comprises the administration of hCG in conjunction with an antiestrogen and/or a Type I Interferon.

15

BACKGROUND OF THE INVENTION

Various patents and scientific articles are referred to throughout the specification. These publications are incorporated by reference herein to
20 describe the state of the art to which this invention pertains.

Breast cancer has caused the death of a quarter of a million women worldwide for many years and has been estimated to be the leading cause of death in women aged
25 between 35 to 54, being second only to cardiovascular diseases in women aged over 55 (W.P.D. Logan, Cancer of the female breast. International mortality trends. W.H.O. Stat. Rep. 28:232, 1975).

Breast cancer accounts for 27% of all
30 malignancies around the world. Despite improvements in early detection of this disease, its incidence is increasing and its mortality rate has not significantly

-2-

decreased. There is a well-known association between early full term pregnancy and a reduction in the lifetime risk of developing breast cancer, however the mechanisms mediating this protective effect have not been

5 elucidated.

In the rat model, completion of a full term pregnancy prior to carcinogen administration inhibits tumor production. Maximal mammary tumor incidence occurs when the carcinogen is administered to young rats (Russo and Russo, 1987, Lab. Invest. 57:112-137; Russo and Russo, 1978, J. Natl. Cancer Inst. 61:1439-1442; Russo et al., 1979, Am. J. Pathol. 96:721-734). Tumor incidence decreases significantly, or becomes almost completely abolished when the carcinogen is administered to parous rats between 3 and 9 weeks post-delivery with or without lactation (Russo and Russo, 1980, Am. J. pathol. 100:497-511; Russo and Russo, 1980, Cancer Res. 40:2677-2687; Russo and Russo, 1982, Internat. Res. Com. (IRCS) 10:935-945; Russo and Russo, 1993, European J. Cancer Prevention 2:101-111).

The role played by endocrine treatment in breast cancer was discovered in 1896, when Bateson observed that breast cancer in pre-menopausal women undergoes remission after oophorectomy. This finding, subsequently confirmed by other scientists, supported the evidence that at least some breast tumors are directly dependent on hormones for their growth and created interest in the therapeutic approach of endocrine organ ablation for the purpose of removing the endogenous source of hormones.

As drugs specifically antagonizing the estrogen action were discovered, they became an attractive alternative to surgical ablation. Several anti-estrogen

-3-

compounds have been tested in pre- and post-menopausal women in phase I and II clinical trials. So far, Tamoxifen has proved to be the drug best approaching the effectiveness of surgical endocrine therapy and the one that is substantially free from serious side effects. A comprehensive review of the therapeutic efficacy of antiestrogens in the treatment of breast cancer can be found in Legha & Carter, Antiestrogens in the treatment of breast cancer. (Cancer Treat. Rev. 3:205, 1976.).

Another review more specifically related to clinical experience with Tamoxifen is that of Paterson et al, A review of the International clinical experience with Tamoxifen. (Jpn. J. Cancer Clin. 11 (Suppl.): 157, 1981).

Approximately one-third of women with breast cancer respond to antiestrogen-based hormonal therapy, while an increase up to 70% of response is expected in patients with receptor-rich tumors. In fact, estrogen receptor (ER) status has been demonstrated to be predictive of response in breast cancer patients (Allegra, J.C., Reviews on Endocrine related cancer. Paterson AHG, Lees AW eds Suppl. 14:115, 1984).

Chorionic gonadotropin is a glycoprotein hormone composed of two non-covalently linked (α and β) subunits. (Labrie, Glycoprotein hormones: gonadotropins and thyrotropin. In: Hormones - From Molecules to Disease. Beanlien EE and Kelly PA - Chapman and Hall, New York and London, pp 257-275, 1990). It is synthesized early in pregnancy by the developing embryo and throughout the gestational process by the syncytiotrophoblast of the placenta, and it is secreted in urine.

Human chorionic gonadotropin is obtained from the urine of pregnant women for both experimental and

clinical uses. The hormone can also be prepared via the recombinant route (WO 85/01959) The main known function of hCG is the stimulation of gonadal steroid hormone production through its interaction with the LH/CG

5 receptor, which is present in the granulosa cells of the ovary in the female and in the testicular Leydig cells in the male.

Recent studies have suggested that urinary hCG is a potent preventive agent that inhibits chemically-
10 induced mammary tumorigenesis through the induction of differentiation. (Russo et al., J. Natl. Cancer Inst. 82:1286-1289, 1990). Additional experiments indicated that hCG treatment of rats after exposure to carcinogens also protected them from tumor development (Russo et al.,
15 Br. J. Cancer 62: 2343-2347, 1990). HCG also inhibits the proliferation of normal and neoplastic human breast epithelial cells (Alvarado et al., In Vitro 30A: 4-8, 1994). It has also been found that urinary hCG from various sources has an inhibitory effect on neoplastic
20 cell lines from various organs or systems (Gill et al., J. Natl Cancer Inst. 89: 1797 - 1802, 1997; Albini et al., AIDS 11: 713-721, 1997; Mgbonyebi et al., Proc. Annu. Meet. A, Soc. Cancer Res. 38, PP. A1977, XP002109660, 1997).

25 International Patent Application WO 97/49432 describes the induction of cell death of breast cancer cells *in vitro* by treatment of the cells with urinary hCG. The same effect was observed with various fractions and the hCG β -subunit.

30 Two further studies, both performed in a rat model, showed that urinary hCG has a preventive effect against carcinogen-induced rat mammary tumors (Srivastava et al., Carcinogenesis 18: 1799-1808, 1997 and You et

al., Cancer Research 58/7: 1498-1502, 1998). Rats were pre-treated with daily doses of urinary hCG for several weeks before tumor induction and sacrificed at various time points after continued hCG treatment. In the pre-
5 treated rats, the incidence of carcinoma-induced mammary tumors was reduced.

Women who had undergone urinary hCG treatment for infertility or weight loss also were observed to have a reduced incidence of breast cancer (Bernstein et al.,
10 Cancer Epidemiol., Biomarkers and Prev. 4: 437-440, 1995). These observations were only inferential, however, and studies directed toward measuring the effect of hCG in the treatment of human breast cancer heretofore have not been reported. From the rat model, only a
15 protective effect of urinary hCG on the development of cancer has been deduced when the hCG was administered very close to initiation of carcinogenesis. However, in humans, breast cancer is usually diagnosed only after it is already established as a palpable nodule, or
20 detectable in diagnostic mammography.

U.S. Patents 5,700,781 (Harris, 1997), 5,677,275 and 5,877,148 (Lunardi-Iskandar et al., 1997, 1999), as well as International Patent Application WO96/04008 disclose methods for treating cancers like
25 Kaposi's sarcoma, involving the administration of urinary hCG. For Kaposi's sarcoma, which is believed to be of endothelial origin, the hCG seemed to have an anti-proliferative effect when injected into mice having established, metastatic Kaposi's sarcoma.

30 Recently, the anti-tumor effects of hCG were questioned by a series of experiments reported by the group of Robert Gallo (Lunardi-Iskandar et al., Nature Med. 4: 428-434, 1998 and comments at pages 370 and 390-391 of the same issue). These experiments convincingly

-6-

showed that the anti-Kaposi's Sarcoma (KS) effect of hCG preparations are not due to the hCG itself, but instead to an unidentified urinary factor, referred to as HAF (hCG-associated factor). A number of commercially
5 available hCG preparations (clinical grade and purified), as well as subunits, fragments and recombinant hCG, were tested for their inhibitory activity on neoplastic KS cells *in vitro* and in *in vivo* animal models. Neither purified urinary nor purified recombinant hCG, subunits
10 or fractions of hCG had any effect in the *in vivo* animal model or *in vitro* assay, respectively.

The fact that early pregnancy of mice leads to KS tumor regression even though mice do not produce hCG at all further supports these findings.

15 Taken together, evidence accumulated that the beneficial effects of hCG in treating cancer were just an artifact of insufficient protein purification, the actual anti-tumor agent being an as-yet unidentified factor associated with early pregnancy. The results obtained
20 with recombinant hCG, together with the fact that the source of the hCG-associated factor "HAF" was first-trimester pregnancy human urine, ruled out the possibility of obtaining any anti-tumor activity from recombinant hCG preparations.

25

SUMMARY OF THE INVENTION

The inventors of the present invention have now made the surprising discovery that both urinary as well as recombinant hCG is effective in the treatment of human
30 breast cancer. This finding overcomes the prejudice created within the scientific community by the experiments of Gallo et al., outlined above (Lunardi-Iskandar et al., *supra*), wherein the anti-tumor activity was not traced back to hCG.

-7-

The present invention therefore relates to the use of hCG for the manufacture of a medicament for the prevention of mammary tumors, and to corresponding pharmaceutical compositions, methods of treating patients
5 with those pharmaceutical compositions, and articles of manufacture comprising such pharmaceutical compositions.

In addition, the inventors have found that hCG is effective in the treatment of conclamate human mammary tumors, i.e., mammary tumors that are already clinically
10 manifest.

The present invention also relates to the use of hCG for the manufacture of a medicament for the treatment of clinically manifest or evident mammary tumors, and to corresponding pharmaceutical compositions,
15 methods of treating patients with those pharmaceutical compositions, and articles of manufacture comprising such pharmaceutical compositions.

Other features and advantages of the present
20 invention will be better understood by reference to the drawings, detailed description and examples that follow.

BRIEF DESCRIPTION OF THE DRAWINGS

Figure 1. Histogram showing the effect of r-
25 hCG treatment on the proliferative index of primary human breast cancers (ki67+ cells). Women with clinically apparent, newly diagnosed cancer of the breast underwent pre-treatment needle biopsies of the breast mass. They then received either every other day injections of 500
30 mcg r-hCG, or no treatment. The breast mass was then removed by lumpectomy or mastectomy. The proliferative index of the needle biopsies and excised tumors were

determined by immunohistochemical staining for Ki67+ cells.

Figure 2. Histogram showing the effect of r-hCG treatment on the estrogen receptor expression of primary human breast cancers (Er+ cells). Women with clinically apparent, newly diagnosed cancer of the breast underwent pre-treatment needle biopsies of the breast mass. They then received either every other day injections of 500 mcg r-hCG, or no treatment. The breast mass was then removed by lumpectomy or mastectomy. The estrogen receptor expression of tumor cells in the needle biopsies and excised tumors were determined by immunohistochemical staining for Er+ cells.

Figure 3. Histogram showing the response evaluation of patients with metastatic breast cancer who were treated with r-hCG. The patients were categorized as follows: PD = progressive Disease; SD = Stable Disease; PR = Partial Response; CR = Complete Response.

Figure 4. Schematic diagram of experimental protocol designed for testing the preventive and therapeutic efficacy of recombinant and urinary human chorionic gonadotropin (hCG) on rat mammary cancer *in vivo*.

Figure 5. Effect of Placebo, r-hCG and u-hCG on tumor burden. Number of tumors per animal in virgin rats treated with placebo, Regimens 1 (R1), 4 (R4), and 9 (R9); recombinant hCG, Regimens 2 (R2), 5 (R5), and 7 (R7), or urinary hCG, Regimens 3 (R3), 6 (R6), and 8 (R8) at the times indicated in Figure 4.

Figure 6. Graph showing time-course of inhibition of tumor burden in rats by r-hCG and u-hCG.

Figure 7. Proliferation experiments using the human breast cancer cell line CG-5. The cells were grown

-9-

in a culture medium containing a fixed amount of Tamoxifen (TAM) and various concentrations of hCG. Cells were counted after 3 days (Fig. 7A) and 6 days (Fig. 7B) and cell counts are expressed as the percent of the number of control cells. Dotted line represents the effect of 10^{-7} M tamoxifen alone. The tamoxifen is added either simulataneously with (solid circles or sequentially to (solid triangles) the hCG.

Figure 8. Histogram showing results of proliferation experiment using the human breast cancer cell line CG-5, wherein the culture medium was supplemented with hCG alone.

DETAILED DESCRIPTION OF THE INVENTION

In accordance with the present invention, it has now been shown that hCG is effective in the prevention of mammary tumors and in the treatment of conclamate human mammary tumors, i.e. of mammary tumors, which are already clinically manifest. The invention therefore relates to the use of hCG for the manufacture of a medicament for the prevention of mammary tumors and for the treatment of clinically manifest or evident mammary tumors.

Clinically manifest is to be understood as being detectable using clinical diagnostic methods, as palpation, mammography, ultrasound or other imaging diagnostics as thermography, light scanning, xeroradiography or Magnetic Resonance Imaging (MRI), scintigraphy and so on, but also the diagnostic detection from histological examination of biopsy material, as for example fine-needle aspiration biopsy, or form serological markers.

-10-

In a preferred embodiment, the clinically manifest tumor is a primary tumor, meaning that the tumor has not been disseminated and infiltrated other tissues, but is still at the primary site where it developed.

5 Preferably, the primary tumor is a non-invasive carcinoma, such as ductal carcinoma *in situ*, derived from the epithelium of the mammary gland duct, or lobular carcinoma *in situ*, derived from the secretory epithelium of the mammary gland.

10 In another embodiment, the tumor is an invasive carcinoma, which can be invasive tubular or lobular (glandular) carcinoma or any other invasive or infiltrating breast cancer. The tumors treated according to the invention can also be of other histological types,
15 such as medullary, mucinous, papillary and the like.

Breast cancer exists in women and in men. However, it is highly prevalent in women. Breast cancer can occur in premenopausal or postmenopausal women. The invention therefore also relates to the use of hCG for
20 the manufacture of a medicament for the treatment and/or prevention of mammary tumors in premenopausal or postmenopausal women, though it may be used to treat breast cancer in men as well.

As can be taken from the clinical studies on
25 postmenopausal women presented in Example 2 below, the women treated had bi-dimensionally measurable or palpable lesions and clinical evidence of metastatic disease, and hCG had a positive effect on the course of the illness in more than 50% of the patients. The invention therefore
30 preferably relates to the treatment of mammary tumors in postmenopausal women. The invention also relates to the use of hCG for the manufacture of a medicament for the treatment and/or prevention of metastatic mammary tumors.

-11-

Highly preferred is the use of hCG for the preparation of a medicament for treatment of metastatic mammary carcinoma in postmenopausal women.

5 In another preferred embodiment, hCG is used as an adjuvant in combination with other cancer therapies. Other cancer therapies include, for example, mastectomy, lumpectomy, segmental mastectomy or any other surgical treatment, as well as chemotherapy, or therapy with drugs or combinations of drugs.

10 For instance, specific endocrine therapies with antiestrogens, progestins or aromatase inhibitors have been found to be effective in treating breast cancer. Antiestrogens are especially effective in the treatment of Estrogen-receptor (ER) positive tumors, since they
15 bind to the ER and competitively block binding of estrogen to its receptor. The invention therefore also relates to the treatment or prevention of breast cancer wherein the treated tumor cells are Estrogen-Receptor positive, and to the use of hCG in combination with an
20 antiestrogen. The administration of hCG and the antiestrogen may be simultaneous, sequential or separate.

The administration of the antiestrogen sequentially to the treatment with hCG is particularly preferred. The antiestrogen particularly well suited is
25 Tamoxifen, which may be administered orally in a daily amount of about 30 milligrams (mg). Although Tamoxifen is the preferred antiestrogen, other substances having analogous activity are within the meaning of "antiestrogen" in accordance with the present invention.
30 Suitable examples are found, e.g., in a review by Legha and Carter: "Antiestrogens in the treatment of breast cancer" (Cancer Treat. Rev. 3:205, 1976).

-12-

The amount of hCG administered according to the invention is 100 to 20,000 International Units (IU) per day or equivalent microgram (μ g) amounts. The unit "IU" is specifically adapted to biologically active substances. The International Unit "IU" of hCG is the activity contained in a stated amount of the International Standard, which consists of a mixture of freeze-dried extract of chorionic gonadotrophin from the urine of pregnant women, with lactose. The equivalence in the International Units of the International Standard is stated by the World Health Organization. The potency of hCG is expressed in International Units per milligram. The determination of the potency is described in *European Pharmacopoeia* 1997, pp. 913-914 or in *USP, Gold/Official Monographs*, p. 718. The protein content of a preparation can be measured by any protein determination assay known in the art, as for example by the Lowry protein assay or Bradford protein assay, based on measuring optical density, as well known by persons skilled in the art.

Commercial urinary hCG preparations have a specific activity range of 2,000 to 10,000 IU/mg, for example. Recombinant hCG preparations may have a specific activity as high as 20,000 IU/mg. Daily doses in the range of 5,000 to 10,000 IU/day/patient are preferred. Using mass to calculate dosage, hCG may be administered in an amount of 50 to 10,000 micrograms per patient per day. An amount of 250 to 3,000 micrograms per patient per day is preferred. Preferably, hCG administered every second day, or three times a week.

The duration of hCG administration preferably is several weeks. In particular, the administration of hCG every two days lasts for about 12 weeks. A highly preferred regimen is an administration every two days for

-13-

about 12 weeks, a regimen that is particularly applicable to the treatment of metastatic breast cancer in post-menopausal women.

The hCG may be administered locally, i.e.
5 directly into or onto the tumor, or it can be administered into the blood stream. It can also be administered intramuscularly. In a preferred embodiment the administration is subcutaneous.

The present invention also provides
10 pharmaceutical compositions containing a pharmaceutically active amount of an hCG and an antiestrogen, in the presence of one or more pharmaceutically acceptable excipients, for the simultaneous, sequential or separate use of its active components in the treatment of breast
15 cancer.

Suitable pharmaceutically acceptable excipients include any and all solvents, dispersion media and the like which may be appropriate for the desired route of administration of the pharmaceutical preparation. The
20 use of such excipients for pharmaceutically active substances is known in the art. Except insofar as any conventional media or agent is incompatible with the compositions to be administered, its use in the pharmaceutical composition is contemplated. In preferred
25 embodiments, the pharmaceutical compositions contain hCG or a biological equivalent thereof (preferably 250-500 μ g hCG) and a sugar (preferably 30-60 mg sucrose) in a phosphate buffer. The preparation preferably is lyophilized for storage and transportation, then re-
30 constituted with water or saline before use.

The pharmaceutical compositions according to the invention is administered in an amount of 100 to 20,000 IU or equivalent mass amounts calculated from the

-14-

specific activity (preferably about 500 μ g, equivalent to about 10,000 IU), preferably to be administered subcutaneously. The antiestrogen preferred for use in the pharmaceutical compositions of the invention is

5 Tamoxifen, which is administered orally in a daily amount of about 30 milligrams.

Interferons (IFNs) are a well-known family of proteins which have been shown to possess both antiviral and cell growth inhibitory effects. Therefore, a

10 preferred embodiment of the invention makes use of an interferon, preferably a Type I Interferon in the treatment of breast cancer in combination with hCG and an antiestrogen. This combination further reduces the growth of breast cancer cells. The term "Type I Interferon" is

15 intended to include IFN- α (alpha), IFN- β (beta), IFN- ω (omega) or IFN- τ .

Interferons have a wide range of cellular effects on cancer cells, as well as on normal cells, including effects on cell phenotype such as expression of

20 surface antigens and receptors, among others. Experimental evidence indicates that type I IFN modifies the hormone receptor level in breast cancer cells. For instance, Pouillart et al., in "Administration of fibroblast interferon to patients with advanced breast

25 cancer: possible effects on skin metastasis and on hormone receptors" (Eur. J. Cancer Clin. Oncol. 18:929-935, 1982) described the effect of human fibroblast interferon administered to patients with metastasized breast cancer and found an increase of the receptors for

30 estrogens and progestins. It is for these reasons that the present invention includes the use of hCG and Type I Interferon in conjunction with an antiestrogen in the manufacture of a medicament for the treatment of breast

-15-

cancer as well as a pharmaceutical composition therefor, for the simultaneous, separate or sequential use of its active components in the treatment of breast cancer.

Several forms of hCG may be used effectively in accordance with the present invention. These include the full dimer hCG and any fragment thereof having the similar biological activity of hCG and/or binding activity to the hCG receptor. hCG can be either "native", that is, obtained from natural human sources (urine, for example) or cell lines, or "recombinant", that is, obtained from genetically engineered or otherwise modified bacterial, yeast or eukaryotic cells.

It is well understood that the cellular receptor to which hCG binds also is recognized and bound by luteinizing hormone (LH), a hormone that is also structurally similar to hCG. For this reason, the present invention also includes the use of LH as a substitute for or supplement to hCG in any of the medicaments, pharmaceutical preparations and methods described herein. The appropriate dosage and regimen for administration of LH will be proportionate to that of hCG, wherein, as a rule of thumb, 1 IU of hCG is equivalent to 7 IU of LH.

In view of the common structure between the alpha subunits of FSH (follicle stimulating hormone), TSH (thyroid stimulating hormone), LH and hCG, the present invention is also directed to the use of FSH, TSH and LH fusion proteins, wherein the beta subunit has been modified so that the resulting fusion molecule has hCG-like behavior. Fusion molecules as contemplated herein are described in the art, e.g., by Dias et al., J. Biol. Chem. 269(41): 25289-25294 (1994); and Grossman et al., J. Biol. Chem. 272(24): 15532-15540 (1997).

-16-

The present invention also provides a method of inhibiting the proliferation of breast cancer cells in humans, preferably women, most preferably postmenopausal women, comprising administering to a patient in need

5 thereof an effective inhibiting amount of hCG.

Additionally, the invention provides a method of inhibiting the proliferation of metastatic mammary tumor cells, comprising administering an effective inhibiting amount of hCG.

10 The invention further relates to a method of inhibiting the proliferation of metastatic mammary tumor cells in humans, preferably women, most preferably postmenopausal women, comprising administering to a patient in need thereof an effective inhibiting amount of
15 hCG. In a preferred embodiment, the aforementioned methods comprise additionally administering an effective inhibiting amount of an antiestrogen. In a particularly preferred embodiment, the methods comprise additionally administering a Type I Interferon.

20 The above-described aspects of the present invention relate to the treatment of clinically manifest mammary tumors. It is important to recognize that the experiments that led to these aspects of the invention also demonstrated unequivocally, for the first time, that
25 hCG is efficacious as a prophylactic agent in protecting against mammary tumor development, and as a therapeutic agent in the treatment of existing tumors. This result was surprising in view of the recent reports that hCG was not effective in the treatment of AIDS related Kaposi's
30 sarcomas, thus indicating that the alleged active principle (if any) in urinary hCG preparations is not hCG itself. It is particularly surprising that pre-existing breast carcinomas can be treated with hCG, and more

-17-

specifically with r-hCG, inasmuch as programmed cell death is implicated as the mode of action of urinary hCG in both Kaposi's Sarcoma and breast cancer, and the aforementioned reports attributed the apoptosis activity of urinary hCG preparations to hCG-associated factors (HAFs) and not to hCG itself (Lundardi-Iskandar et al., Nature Medicine 4:428-434, 1998; Samaneigo et al., J. Natl. Cancer Inst. 91:135-143, 1999).

In view of the foregoing unexpected results, the present invention also relates to the use of hCG and particularly r-hCG for the manufacture of a medicament for the prevention of mammary tumors. Also provided are pharmaceutical compositions for the prevention of mammary tumors, which comprise r-hCG alone or in combination with one or more additional prophylactic or therapeutic agents, similar to the pharmaceutical compositions described above for the treatment of clinically manifest mammary tumors. Likewise, a method of preventing mammary tumors is provided, which comprises administering to a patient a prophylactically effective dose of r-hCG, for a duration effective to achieve a protective effect against mammary tumor development.

The dosage of hCG, the dosage regimen and the duration of the treatment for prevention of mammary tumors should be similar to those used for the treatment of clinically manifest tumors. Thus, in a preferred embodiment, the dosage of hCG for a human patient is from 100 IU to 50,000 IU (International Unit) per dosage, and in a more preferred embodiment, 1,000 to 20,000 IU. In a most preferred embodiment, the dosage is 10,000 IU. The dosage regimen may be from once a week to seven times a week, but preferably is on alternate days or three times a week. In another preferred embodiment, the dosage

-18-

regimen is three times a week. The duration of administration of r-hCG preferably is several weeks, and most preferably about 12 weeks.

The use of hCG as a breast cancer preventative is appropriate for a variety of patients. For instance, patients with a family history of breast cancer stand to benefit greatly from this prophylactic measure. Similarly, patients with a personal or family history of other kinds of cancer, particularly hormone related cancer, would be likely candidates for preventative hCG treatment. The treatment preferably is administered to persons who have not undergone full-term pregnancy.

Articles of manufacture are also provided in accordance with the invention, to facilitate the use of hCG (including u-hCG, r-hCG, hCG β -subunit or any other hCG fragment or derivative having anti-cancer activity), hLH or fusion proteins comprising hCG β -subunit and corresponding subunits of FSH, TSH or LH, in a medicament, or as part of a pharmaceutical composition, in the above described methods for preventing mammary tumors or treating clinically manifest mammary tumors. Such articles of manufacture include packaging material, an hCG pharmaceutical composition within the packaging material, and a label that indicates that the pharmaceutical agent contained therein is useful for the prevention or treatment of mammary tumors.

The following examples are provided to describe the invention in greater detail. They are intended to illustrate, not to limit, the invention.

EXAMPLE 1**Recombinant Human Chorionic Gonadotrophin Inhibits
Primary Mammary Tumor Growth in Postmenopausal Women**

5 The efficacy of hCG was evaluated by treating
with this hormone patients with newly diagnosed primary
breast cancer. The efficacy of treatment was assessed by
determining whether administration of 10,000 IU hCG on
alternate days for 2 weeks to women with newly diagnosed
10 breast cancer will reduce tumor size, inhibit cell
proliferation, and modify the percentage of cells
expressing estrogen and progesterone receptors. The
systemic effect of the hormone was evaluated by
determining serum levels of pituitary and ovarian
15 hormones at various times of treatment. R-hCG was used
in this study.

Patient Selection and Accrual. Twenty-five
postmenopausal women took part in the study. The
patients had palpable and bidimensionally measurable
20 primary breast cancer larger than 1.5 cm in clinical
diameter. The tumor was confirmed by histopathological
analysis. No evidence of metastatic disease was observed
when entering the study. Patients had adequate bone
marrow, hepatic and renal function. Patients with
25 ulcerated tumors, skin involvement of inflammatory breast
cancer were excluded. No concomitant pituitary nor
ovarian tumors were observed among the patients. There
was no active thrombophlebitis or a history of allergy to
hCG. None of the patients had hormonal replacement
30 therapy. A routine staging procedure consisted of
cytological evaluation of a needle puncture of the
suspected lesion, medical history, thorough physical and
gynecological examination, chest radiograph, sonography
of the liver, abdomen and pelvis, bone scintigraphy,

-20-

blood examination - including CA 15.3 tumor marker, mammography and sonography of the breasts. The primary tumor was measured by clinical examination, mammography and sonography immediately before surgery.

5 **Specimen Collection and Post-Surgical**

Treatment. After informed consent, the patient underwent core biopsies of the primary tumor under local anesthesia with a pistol fitted with a 12 to 14 gauge tru-cut type biopsy needles (Bard, Covington, USA). This procedure
10 represents the standard of care, therefore no departure from routine diagnostic procedures was required. The core needle biopsy was examined by frozen section technique. If the frozen section was positive for malignancy, then three additional needle biopsies were
15 obtained from the tumor for evaluating the surrogate markers listed below. On the same day 0 (pretreatment) a serum sample was taken for determination of basal levels of inhibin, estrogen, progesterone, FSH, LH and the beta subunit of hCG. The serum sample, as was the case for
20 all subsequent sera, was derived from the blood sample and frozen immediately at -70°C until the day of shipment to the research laboratory. The other serum samples were obtained at days 5, 9 and 13. At day 15 of hCG treatment the patient underwent surgery, which consisted of
25 mastectomy when the tumoral mass (including 'in situ' components) was considered to be larger than 3 cm; otherwise the breast was conserved and a lumpectomy was performed. Breast conservation was only practiced when the surgical margins were free of disease. Lymph node
30 dissection of the axilla was routinely performed. All resected tissues was sent to the laboratory of pathology for microscopical examination.

-21-

After surgery the patients underwent adjuvant treatment. It consisted of 20 mg per day Tamoxifen when the tumor was larger than 3 cm or pathological lymph nodes were present. Hormonal adjuvant therapies are normally continued for 5 years. Post-surgical radiation was performed in those cases in which the breast was preserved, when the margins of resection on the chest wall were positive, or when the tumors were medially located. The breast was irradiated up to 50 Gray in 25 fractions of 2 Gray. The site of the primary tumor was boosted up to 66 Gray. The subclavicular lymph nodes and chest wall received a dose of 46 Gray in 23 fractions of 2 Gray. Each week 5 fractions were delivered. After primary treatment the patient was seen every three months for clinical examination and blood chemistry. Yearly, a radiological control was performed as well. In case of recurrent disease, treatment for recurrent breast cancer was initiated.

Hormonal Treatment: Dose and Schedule. The patients selected for this study received intramuscularly (IM) 10,000 units of the experimental drug, recombinant human chorionic gonadotropin on days 1, 3, 5, 7, 9, 11 and 13. The lyophilysate was reconstituted with normal physiological saline immediately before injection in the gluteus. The controls were blinded and received IM injections of placebo. At each injection the patients were seen and informed about there concurrent medication and possible side effects. Treatment was double blind with 20 active sets and 5 controls. No dose modification was allowed. When side effects occurred or concomitant clinical problems, the treatment was interrupted as was the case in one patient. The efficacy of treatment was assessed by evaluating in the residual tumor resected by

-22-

lumpectomy or mastectomy at the end of the two-week r-hCG treatment the same parameters evaluated in the initial core needle biopsies.

Surrogate Marker Analysis. The effects of r-hCG on the breast tumors was evaluated by using immunocytochemistry, performed in both core biopsies of the tumor and in residual tumor present in lumpectomy or mastectomy specimens. The following surrogate markers were evaluated using immunocytochemistry: Rate of cell proliferation, percentage of cells positive for estrogen (ER) and progesterone receptors (PgR) and immunoreactivity for inhibin. The microscopic analysis of these surrogate markers were performed by selecting fragments of tumor as distant as possible from the sites in which needle biopsies had been performed in order to avoid confounding effects induced by healing and inflammation. The study of lymph nodes of the same patients from which the primary tumors were studied was also analyzed by the same techniques.

Breast Tumor Tissue Processing. One core biopsy of the breast tumor was performed in each patient selected for this protocol. The core biopsy was frozen and histologically analyzed by the pathologist. If the diagnosis of invasive carcinoma was made, three additional cores of tumor tissues were obtained at the time of the initial diagnosis. The cores were fixed in 10% neutral buffered formalin (NBF) for their histopathological and immunocytochemical analysis. The surgical specimens containing the tumor, i.e., lumpectomies or mastectomies, were fixed in NBF and representative fragments of the residual tumor and normal breast tissue distal to the tumor were sent to the clinical laboratory. Lymph nodes that were found to be

-23-

positive for metastasis during axillary dissection were fixed in NBF, embedded in paraffin, and representative tissue blocks were also submitted. Every specimen was identified with the patient trial number, date in which

5 the specimen was obtained, and whether it was the initial needle biopsy of tumor or of normal tissue, or the final (second) operative specimen consisting of either tumor or normal tissue. Formalin-fixed needle biopsy and tumor specimens were shipped to the clinical laboratory by

10 express mail. All specimens were identified upon arrival to the laboratory by experiment number (Exp. 721) and an accession number which was sequentially assigned by date of arrival. All samples were identified at all times by their accession number; patient identity and treatment

15 were disclosed only after all the data had been collected.

IMMUNOCYTOCHEMICAL STUDIES

Antibodies. Cell proliferation - Ki67

20 monoclonal antibody (Oncogene Science, Inc., Cambridge, MA); estrogen receptor - mouse monoclonal anti-human estrogen receptor antibody (ER) (clone ER1D5) (Amac Lab, Westbrook, ME) diluted 1:400; Progesterone receptor (PgR) - mouse monoclonal antibody clone PR10A9 (Immunotech,

25 Inc., Westbrook, ME); rabbit polyclonal antibodies raised against inhibin a and b synthetic peptides synthesized at the laboratory's Protein synthesis Facility were used at a dilution 1:50.

Procedures. Sections of paraffin-embedded

30 tissues were mounted on aminoalkylsilane-coated slides, deparaffinized, rehydrated and endogenous peroxidase was quenched with 2% hydrogen peroxide. After blocking, the sections were incubated with the respective antibodies

-24-

overnight, washed and incubated with horse anti-mouse biotinylated secondary antibody (Vector Laboratories, Inc., Burlingame, CA). Vectastain Elite ABC kit (Vector Laboratories, Inc., Burlingame, CA) was used to conjugate and 3,3'-diaminobenzidine-HCl (DAB) to reveal the immunocytochemically reacted sites. Sections incubated with non-immune serum were used as negative controls. All sections were lightly counterstained with hematoxylin. Cell proliferation was evaluated by counting the number of cells expressing the nuclear antigen Ki67 in the outer part of the nucleolus and in the granular component of the nucleus. The possibility that intrapersonal variations might be affecting the results were ruled out by evaluating the same specimens several times blindly. Steroid receptor status was evaluated in serial sections reacted with the ER or PgR antibodies by a count of the number of nuclei positive for each one of the receptors. Values were expressed as the percentage of positive cells over the total number of tumor cells present in each tissue section. Immunostaining for inhibin was evaluated by examination of slides under a bright field microscope, and graded according to the intensity of the brown staining as negative (-), weakly (+), moderately (++) or strongly (+++) positive. Comparisons were made between values obtained in the first biopsy and in the tissues resected after 2 weeks of hCG treatment.

Apoptosis was detected in 5 mm sections of formalin-fixed, paraffin embedded tissues obtained as described above. Apoptotic cell nuclei were identified using the Apoptag kit (Oncor, Gaithersburg, MD). Sections were first treated with 20 mg/ml proteinase K in PBS for 20 min. at room temperature, quenched by 0.002%

-25-

H₂O₂ for 30 minutes, equilibrated with buffer, and incubated with terminal deoxynucleotidyl transferase (TdT) for 20-40 min. all procedures performed at room temperature. The sections were then washed with stop
5 buffer for 30 min at 37°C, and incubated with anti-digoxigenin for 30 min at room temperature. Color was developed using 0.05% 3-3-dimethylaminobenzene in 0.01% H₂O diluted with Tris-HCL (pH 7.5) and counterstained with Hematoxylin. The percentage of positive cells over the
10 total number of cells counted represented the Apoptotic Index.

The evaluation of all the immunocytochemical reactions was done blindly by one of the Principal Investigators (JR), without knowledge of the type of
15 treatment received by the patients. Only after all the data were collected and analyzed patient identity and the type of treatment were disclosed with the purpose of tabulating the data.

20 EVALUATION OF SYSTEMIC EFFECTS OF R-HCG

The systemic effects of this hormonal treatment was evaluated by determining serum levels of the pituitary hormones FSH and LH, and the ovarian hormones estrogen, progesterone, and inhibin as markers of hCG
25 activity. Ten ml of blood were drawn on days 0, 5, 9 and 13 of treatment, from 26 patients. The serum was separated immediately upon drawing, frozen at -80°C and the specimens were identified with the patient trial number, date, and sequence in the number in the
30 treatment. The sera were shipped from Belgium to the clinical laboratory in dry ice by express mail. All specimens were identified upon arrival at the laboratory

-26-

by experiment number and an accession number which was sequentially assigned by date of arrival.

Frozen serum samples were shipped to InterScience Institute (ISI), Inglewood, California, for
5 radio immunoassay (RIA) quantitative determination of levels of the following hormones: hCG beta subunit, estradiol, progesterone, FSH; LH; and inhibin. Quantitative determination of beta-hCG was confirmed by SmithKline- Beechman Clinical Laboratories in
10 Philadelphia, PA.

RESULTS

From the twenty five patients entered in this study the histopathological and immunocytochemical
15 analysis could be completed in 22 of the patients. Tissues from three patients were not adequate for analysis because the amount of tumor was either insufficient or not properly preserved for immunocytochemical determination of cell proliferation,
20 steroid receptors or inhibin.

Cell proliferation. The immunocytochemical detection of Ki67 revealed that at the initiation of treatment there was a significant variation in the rate of cell proliferation among the patients, as shown in the
25 needle biopsy (NB) data. The tumors removed after the r-hCG treatment had significantly depressed values, with small interpersonal variations, whereas in those patients receiving the placebo the tumors had a cell proliferation rate almost identical to the initial values. The
30 reduction in cell proliferation was significant ($p < 0.00006$) (Fig. 1) in 17 out the 18 patients that received r-hCG treatment. In nine patients treated with r-hCG lymph nodes found to be positive at the time of

-27-

surgery were available for analysis. In these nodes the metastatic cells had a rate of cell proliferation within the same range than the primary tumor removed at surgery, and significantly lower than in the needle biopsy.

- 5 Positive lymph nodes in a placebo treated patient exhibited the same rate of cell proliferation than the NB and Exc.B. The carcinoma cells metastatic to the lymph nodes had a markedly lower rate of cell proliferation than the germinal centers, which contained numerous Ki67
10 positive cells.

- In order to determine whether the effect of r-hCG treatment on cell proliferation was not masked or altered by the local trauma caused by the core biopsy, we have performed pilot experiments for validating the use
15 of breast core biopsies for determining surrogate end points of cell proliferation in collaboration with Dr. Ingemar Persson, from the Department of Cancer Epidemiology, Uppsala University, Uppsala, Sweden. A pilot study was designed with the purpose of validating
20 data on normal breast morphology and cell proliferation observed in breast core biopsies obtained utilizing a pistol fitted with a 18 gauge needle by their comparison with the same parameters measured in large specimen samples obtained by reduction mammoplasty. Core biopsies
25 were performed in four patients. Each biopsy measured approximately 2 cm in length by 0.2 cm in diameter. The material was fixed in buffered formalin, embedding in paraffin, and stained with hematoxylin and eosin and reacted against Ki67, a proliferating marker. We found
30 the same lobular structures present in the core biopsy were also observed in the surgical specimen. The proliferating activity was not statistically different in the cells from the core biopsy than in those from the

reduction mammoplasty specimens (unpublished observations). These data were confirmed in the present study in which the values of cell proliferation detected in the mastectomy specimen were similar to those detected in the dissected lymph nodes. Altogether, these preliminary data allowed us to rule out the possibility that the effect of r-hCG might have been induced by the local manipulation and not by the administered hormone.

Estrogen and progesterone receptor. The immunocytochemical expression of ER was considered to be positive when greater than 20% of tumoral cells expressed a positive nuclear reaction for this receptor. Based upon this concept, it was found that in six cases r-hCG treatment resulted in a decrease in the ER status from a positive NB to a negative Exc.B (Fig. 2). The lymph node metastases of these patients showed a similar level of ER, except in two cases that expressed an ER content similar to that of the initial biopsy. None of the placebo treated groups showed changes in their receptor content between the initial biopsy and the post-treatment specimen.

The content of PgR was also considered to be positive when more than 20% of tumoral cells were positive for this antibody. In six of the cases in which the initial NB was positive it became PgR negative after treatment. In those cases in which the initial biopsy was negative the post-treatment excisional biopsy was also negative. In five of the cases in which the NB was positive the lymph node metastases were negative for PgR. Placebo treated patients did not exhibit changes in the PgR status of their tumors. Figures 2 and 3 depict the values ER and PR positive cells, respectively, expressed as a percentage.

-29-

Immunostaining for inhibin. In nine out of the eighteen primary breast cancer patients that received r-hCG a significant increase in immunoreactivity was observed in the neoplastic cells. This effect was not
5 observed in the tissue samples of patients that received the placebo.

Hormonal profile. The levels of the six hormones were measured in the serum of breast cancer patients receiving r-hCG or placebo. There was a
10 significant difference in the levels of b-hCG detected in the serum of the patients treated with r-hCG over those receiving the placebo at 5, 9 and 13 days of treatment ($p < 0.0001$, $P < 0.004$ and $p < 0.007$, respectively. There was no statistically significant increase in the level of LH
15 in the r-hCG over the placebo treated patients at any of the time points sampled. Neither the r-hCG nor the placebo treatments modified the levels of FSH, estradiol, inhibin, and progesterone.

20 CONCLUSIONS

In the present work we have demonstrated that a 2-week treatment with r-hCG administered as described above to postmenopausal women with newly diagnosed primary breast cancer induces a marked and significant
25 reduction in cell proliferation in the primary tumor. An interesting observation was that the lymph nodes of the same patients exhibited in the metastatic cells a level of cell proliferation similar to that of the post-r-hCG treatment tumors, but no changes were observed in placebo
30 treated women.

Recombinant hCG treatment induced down-regulation of ER and PgR expression in six out of nine and six out of ten positive cases, respectively. R-hCG

-30-

did not modify the serum levels of estradiol, progesterone, inhibin, FSH or LH, and the values detected were those reported for menopausal women. R-hCG neither produced clinical side effects in the patients or alterations in their hormonal milieu. These observations are the first indication that r-hCG has an antiproliferative effect in primary and metastatic breast cancers without inducing alterations in the overall well being of the patient. The data reported in this work indicate that hCG has a direct effect on neoplastic cells and that the ovarian hormones do not mediate this effect. Our patients are postmenopausal women in which the hormonal milieu clearly shows that it was not affected after the r-hCG administration.

The local production of inhibin by the neoplastic cells was overexpressed in 50% of the primary breast lesions of patients treated with r-hCG. Due to the limitations of the quantitation by pluses, we have only reported those cases in which significance differences were observed. Western blot analysis would be desirable for a quantitative evaluation of this marker.

At systemic level, the only hormone that was elevated by the r-hCG treatment was b-hCG. The correlation between the decrease in cell proliferation and the increase in b-hCG level was striking.

EXAMPLE 2

Recombinant Human Chorionic Gonadotrophin Inhibits Metastatic Breast Cancer in Postmenopausal Women

An open-label, single center study was conducted to test the inhibitory effect of recombinant human chorionic gonadotropin (r-hCG) on metastatic breast

-31-

cancer in postmenopausal women. The primary objective of this study was to assess the effect of r-hCG on the tumor response rate of bi-dimensionally measurable or palpable lesions. The secondary objectives were: i.) to assess
5 the effect of r-hCG treatment on symptoms caused by metastatic breast tumor lesions, ii.) to determine whether r-hCG exerts any adverse systemic effects, iii.) to measure time to tumor progression and, iv.) to
10 determine the effects of r-hCG on endocrinology parameters and tumor markers.

Thirteen postmenopausal women diagnosed with biopsy-proven breast cancer and clinical evidence of metastatic disease were entered in the study. Patients are treated with 500 mcg of r-hCG three times per week
15 for at least two months. Tumor assessment and measurement of target indicator lesions are performed every two months by X-ray, CT scan, MRI or physical examination. After 60 days of treatment, a re-evaluation of metastatic lesions is performed using the same
20 diagnostic procedure(s). In the event of disease progression (i.e., appearance of new tumor or growth of indicator lesions by at least 25% in square dimensions) study treatment is discontinued, otherwise, treatment is continued, with patient re-evaluations every eight weeks,
25 until progressive disease is noted.

One patient died due to complications of breast cancer prior to the 60 day visit, twelve patients completed the 60 day visit. Of these 12, four patients dropped out due to progressive disease and eight patients
30 remain on active treatment in the maintenance phase of the study (Fig. 3). Two patients have been classified as partial responses, on the basis of greater than 50%

-32-

reduction in liver metastases. Six of the thirteen patients had stable disease.

These first clinical data show that hCG is effective in the treatment of metastatic mammary tumors in postmenopausal women.

EXAMPLE 3

Human Chorionic Gonadotrophin Protects Against Tumor Initiation and Inhibits Tumor Growth in Rats at Early and Late Stages of Tumor Development

Having clinically demonstrated the efficacy of hCG in the treatment of primary and metastatic mammary tumors in post-menopausal women, the inventors sought to extend and clarify their observations through the use of an established animal model system. The experimental results set forth in this example demonstrate in the rat model system that urinary or recombinant human chorionic gonadotropin (u-hCG or r-hCG) have a protective effect against development of breast cancer, and a therapeutic effect against early and late stage mammary tumors.

EXPERIMENTAL PROTOCOL AND PROCEDURES

Evaluation of the efficacy of r-hCG in the prevention of mammary cancer: Regimens 1-9 utilized in the experiments described below are shown schematically in Figure 4. The animals utilized in Regimens 1-9 consisted of 450 intact virgin Sprague-Dawley rats that were purchased from Taconic Farms (New York, NY).

The potential of hCG to inhibit the initiation of DMBA-induced rat mammary carcinomas was evaluated in intact virgin rats treated with placebo (Regimen 1); 100 IU r-hCG/day (Regimen 2), or 100 IU u-hCG/day (Regimen 3). All animals were injected daily for 21 days,

-33-

starting when the rats were 45 days old. The carcinogen DMBA was administered as a single intragastric dose (8mg/100g body weight) given 21 days after the last injection of placebo or hormone. Under these protocols

5 the first effect evaluated was the appearance of tumors detected by palpation and their location with regards to specific mammary glands. Other parameters evaluated were the rate of tumor growth, tumor ulceration, and tumor regression or ulcer healing and tumor necrosis in

10 response to the hormonal treatment. These results were correlated with the baseline level of differentiation of the mammary parenchyma, rate of cell proliferation, level of expression of genes controlling programmed cell death, rate of apoptosis and inhibin synthesis in the mammary

15 epithelium at the time of carcinogen administration.

Evaluation of the therapeutic efficiency of r-hCG on mammary cancer. The tumoristatic and tumoricidal efficacy of r-hCG and u-hCG on early and advanced mammary cancer was tested in intact virgin rats that had received

20 a single dose of DMBA when they were 45 days old (Figure 4, Regimens 4-9). The effect on early tumor development was tested under Regimens 4, 5, and 6. It was evaluated by initiating r-hCG treatment 20 days after DMBA administration, when early lesions, such as intraductal

25 proliferations (IDPs) and carcinomas *in situ* (CIS) are already present, but there are no palpable tumors as yet. The effect on advanced tumor development was evaluated by starting the hormonal treatment 60 days after DMBA administration, or when palpable tumors had reached at

30 least 1 cm in maximal diameter (Regimens 7, 8, and 9). In both groups the hormone was administered for 40 days and final tumorigenic response was evaluated 20 weeks post-DMBA administration. The effect of the hormonal

-34-

treatment on the rate of tumor growth, with special emphasis on tumor regression, absence of skin ulceration, and final tumor size and necrosis were evaluated at the time of assessment of the final tumorigenic response.

- 5 These results were correlated with the rate of cell proliferation, expression of inhibin synthesis, estrogen and progesterin receptor content, expression of programmed cell death genes and of apoptosis in tumors developed by r-hCG and u-hCG treated animals in comparison with those
10 developed by rats that received the placebo.

All treatments were initiated when the animals were 45 days old. For Regimen 1 fifty rats received a daily intraperitoneal (ip) injection of 0.5 ml placebo for 21 days. Under Regimens 2 and 3 the same number of
15 animals received for 21 days 100 IU/day of r-hCG or u-hCG (Steris Laboratories, Phoenix, AZ) respectively. Twenty-one days after completion of the last injection, when the animals were 87 days old, the three groups of animals were inoculated with a single intragastric (ig) dose of 8
20 mg DMBA (Sigma Chemical Co., St. Louis, MO) per 100 g body weight (bw). Thereafter all the animals were palpated periodically for detection of tumor development and determination of tumor growth rate. Final tumorigenic response was evaluated 15 weeks after
25 administration of DMBA.

For Regimens 4-9, 300 animals were inoculated with a single ig dose of 8 mg DMBA/100 g bw when they were 45 days old. Tumorigenic response was evaluated by palpation of the right and left mammary cervical,
30 thoracic, abdominal and inguinal areas and from ventral to dorsolateral extensions of the glands. All tumors were sequentially numbered in the order they had appeared, their location was recorded, and the rate of

-35-

tumor growth was determined by measurement of tumor size with a Vernier caliper. All changes in the health status of the animals, rapid tumor growth or skin ulceration were recorded. Those animals in which the tumors were
5 excessively large or became ulcerated were euthanized, irrespectively of the stage of the hormonal treatment, in compliance with IACUC regulations. Those animals that were euthanized before initiation or before the completion of the hormonal treatments were deleted from
10 the statistical analysis of the final tumorigenic response.

Regimens 4-6 were designed for testing the effect of the hormonal treatments on early tumor development. Twenty one days after DMBA administration
15 those animals allocated to Regimen 4 started receiving a daily ip injection of 0.5 ml placebo for 40 days. Under Regimens 5 and 6 the same number of animals received for 40 days 100 IU/day of r-hCG or u-hCG, respectively. All the animals were palpated biweekly for detection of tumor
20 development and determination of tumor growth rate. Final tumorigenic response was evaluated 20 weeks after administration of DMBA.

Regimens 7-9 tested the effects of r-hCG and u-hCG on late (palpable) tumor development: Sixty days
25 after DMBA inoculation, when the rats were 105 days old, animals allocated to Regimen 7 started receiving a daily ip injection of 100 IU/day r-hCG for 40 days. Under Regimens 8 and 9 the same number of animals received for 40 days 100 IU/day of u-hCG or 0.5 ml placebo,
30 respectively. Tumorigenic response was evaluated by biweekly palpation. All tumors were sequentially numbered, their location was recorded, and the rate of tumor growth was determined by measurement of tumor size

-36-

with a Vernier caliper. Final tumorigenic response was evaluated 20 weeks after administration of DMBA.

Evaluation of Final Tumorigenic Response. At the end of the experiment all the animals were

5 anesthetized with an ip injection of Ketamine (90 mg/Kg bw)-Nembutal (40 mg/Kg bw), bled through the inferior vena cava, and the serum was separated and kept frozen at -70°C. The tumors were rapidly dissected, measured in three dimensions, and serially sliced. Adjacent slices

10 were:

- 1) fixed in 10% neutral buffered formalin (NBF) for histopathological and immunocytochemical analysis,
- 2) frozen in liquid nitrogen for RNA extraction,
- 3) frozen in liquid nitrogen for estrogen receptor (ER)-
- 15 progesterone receptor (PR) determinations, and
- 4) placed in sterile culture medium for DNA analysis by flow cytometry.

Tumors that were smaller than 1 cm in diameter were fixed in 10%NBF only. In the absence of tumors the

20 right thoracic (2nd and 3rd), and the right abdominal (4th) mammary glands were fixed in 10% NBF for histopathological evaluation of degree of gland development. The right and left ovaries of all animals were dissected, measured in three dimensions with a

25 Vernier caliper and fixed in 10%NBF. All the internal organs were examined for evidence of metastatic nodules, adhesions, or hemorrhages. Liver, spleen, and lung changes were documented and representative fragments of tissues were fixed in 10% NBF for histopathological

30 examination. Representative lesions were photographed.

The following criteria were utilized for evaluating the final tumorigenic response:

-37-

1. **Rate of tumor growth**, based on sequential measurement of the two largest diameters of tumors in live animals utilizing a Vernier Caliper and expressing the results in mm.

5 2. **Final tumor size**, based on measurement of the length, width and height of dissected tumors with a Vernier Caliper. Results were expressed in mm. A progressively smaller tumor size in successive measurements was indicative of tumor regression.

10 Palpable tumors that had disappeared at the time of dissection were considered to be 100% regressed. The mammary tissue in which the tumor had been originally identified was fixed in 10% NBF for histopathological analysis. This criterion was indicative of an inhibitory

15 effect of the hormonal treatments on tumor growth.

 3. **Tumor necrosis in large palpable tumors.** Even though in hormonally treated animals the mammary tumors retained their original size or continued growing, upon dissection the tumors were observed to consist of a

20 soft cystic formation filled with necrotic tissue in which there was almost no viable tissue. These signs were interpreted to be indicative of tumor destruction induced by the hormonal treatment, and equivalent to tumor regression induced by the hCG treatment.

25 4. **Presence of skin ulceration in live animals**, indicative of rapid rate of tumor growth, more frequently found in placebo treated animals. This condition made it mandatory to euthanize the animals.

 5. **Statistical Analysis.** The significance of

30 the differences in tumorigenic response among the groups was determined by Chi Square analysis and Student's T test.

RESULTS

Effect of r-hCG and u-hCG in the prevention of mammary cancer-Regimens 1, 2, and 3. Virgin rats treated with placebo, r-hCG or u-hCG for 21 days, and that
5 received DMBA 21 days after the last injection when they were 87 days old, appeared healthy throughout the length of the study. One animal of Regimen 1 and one of Regimen 2 died as a consequence of acute reaction to the anesthesia and were deleted from the study, reducing the
10 total animal population to 49 in each one of these two regimens. None of the animals required to be euthanized before the end of the experiment. The vast majority of tumors were found at the time of autopsy and none of them were ulcerated.

15 Treatment of the animals with hCG significantly reduced the number of tumors in all the mammary glands and no tumors were found in the neck and ear region (ear duct tumors); the number of animals with tumors was reduced from 22/49 (22 of 49 total animals) to 4/49 or
20 6/50, respectively, for r-hCG and u-hCG. As shown in Figure 5, the number of tumors per animal was also significantly decreased, from 0.89 (placebo) to 0.10 (r-hCG) and 0.14 (u-hCG), respectively.

Effect of r-hCG on early tumor development.
25 **Regimens 4, 5, and 6.** From the 50 animals inoculated with DMBA one animal from Regimen 4 and one from Regimen 5 died due to acute reaction to the anesthesia. The treatment of the remaining animals with placebo, r-hCG, or u-hCG was initiated 21 days after administration of
30 the carcinogen (Fig. 4).

Ten of the 49 animals of Regimen 4 (placebo) had developed at least one palpable tumor by 42 days post-DMBA administration. One animal that was severely

-39-

ill and died at the time of the fourteenth placebo injection was deleted from the final analysis. Two animals that died 12 and 14 days after the last injection were included in the final analysis. One of these was
5 free of tumors and the other had three palpable tumors.

As observed in the preventative regimens, treatment of the animals with hCG significantly reduced the number of tumors in mammary glands and non-mammary tissue; the number of animals with tumors was reduced
10 from 48/49 to 38/49 or 30/46, respectively, for r-hCG and u-hCG. As shown in Figure 5, the number of tumors per animal was also significantly decreased, from 5.6 (placebo) to 2.2 (r-hCG) and 1.9 (u-hCG), respectively.

Effect of r-hCG on advanced tumor development.

15 Regimens 7, 8, and 9. From the 50 animals inoculated with DMBA one animal from Regimen 7 died during carcinogen administration and was deleted from the study. From the final analysis of tumorigenic response were also deleted all those animals that needed to euthanized
20 because of the rapid growth and ulceration of the tumors before completion of treatment. The same criteria applied to the animals treated with r-hCG (Regimen 7), u-hCG (Regimen 8), and placebo (Regimen 9).

In the placebo treated animals (Regimen 9) a
25 total of 40 animals were euthanized after completion of treatment and adequate follow up. Thirty nine of them had a total of 229 tumors, with an average of 5.7 tumors per animal, in a distribution similar to that observed for regimens 1-6. In addition two animals had metastatic
30 nodules in the spleen, liver, and lung, which were not included in the final tabulation of tumors.

In the r-hCG treated group (Regimen 7), a total of 37 animals fulfilled the eligibility criteria to be

-40-

included in the final analysis; 33 of them developed a total of 147 tumors, averaging 4.4 tumors per animal with tumors, or 3.9 tumors per total number of animals at risk. Thirty two out of the 36 animals treated with u-
 5 hCG (Regimen 8) developed tumors, with an average of 3.4 tumors per animal.

Results of regimens 1-9 are summarized in Table 1 below, and are shown in Figures 5 and 6.

10 **Table 1.** Summary of Tumorigenic Response in Animals Treated with placebo, Regimens 1, 4, and 9; r-hCG, Regimens 2 5 and 7, or u-hCG, Regimens 3, 6, and 8.

Regimen	No. Animals	No. An. With Tumors	Percent-age ¹	Total No. Tumors	No. Tumors/Animal
1	49	22	44.9	44	0.89
15 2	49	4	8.1	5	0.10
3	50	6	12.0	7	0.14
4	49	48	97.9	273	5.6
5	49	38	77.5	111	2.2
6	46	30	65.2	88	1.9
20 9	40	39	97.5	229	5.7
7	37	33	89.1	147	3.9
8	36	32	88.8	122	3.4

¹ Significant differences in tumor incidence analyzed by Chi square were: Regimen 1 versus Regimen 2=16.96, p<0.00003; Regimen 1 versus 3=13.20, p<0.0002; Regimen 4 versus Regimen 5=9.49, p<0.0018; Regimen 4 versus Regimen 6=17.3, p<0.00003. The differences between r-hCG Regimens 2, 5, and 7, versus u-hCG, Regimens 3, 6, and 8, and between Regimens 9, 7, and 8 were not significant.

30 CONCLUSIONS

The results set forth above indicate that administration of urinary or recombinant hCG to young virgin rats prevents the initiation and inhibits the progression of DMBA-induced tumors. A 21 day treatment
 35 with r-hCG produces a preventive effect, even when the treatment had been terminated 21 days prior to carcinogen administration. Similar results were obtained with u-hCG.

-41-

The results also revealed that r-hCG treatment of rats previously inoculated with DMBA inhibited the development of early mammary lesions, since initiation of the hormonal treatment 20 days after carcinogen administration reduced significantly both tumor incidence and tumor burden. Both r-hCG and u-hCG exhibited similar tumor inhibitory effects. These data have a significant clinical implication, because they indicate the usefulness of the utilization of this hormonal treatment on early as well as on premalignant lesions. These results show that the sooner a treatment is started, the more efficient is the therapeutic effect of these hormones.

When the hormonal treatments were initiated 60 days after administration of DMBA, tumor burden, expressed as the number of tumors per animal, were also significantly depressed. Figure 6 clearly shows that both r-hCG and u-hCG reduce significantly the tumor burden and reduce the growth of tumors, as evidenced by the lower number of tumors per animal after cessation of the hormonal treatments. The analysis of the final tumorigenic response demonstrated that the placebo treated animals had 40% more tumors than those treated with either hormone (Fig. 5). It is important to analyze the slope of the curve between the initiation (start) and finalization (stop) of the treatment shown in Figure 6. Both hormones induce a decline in the slope of the curve due to the direct effect of the hormones on tumorigenesis. At the end of treatment the slope of the curve became steeper, but it never reached that of the animals that had received the placebo, an indication that both hormones have an efficient therapeutic effect by reducing tumor burden by 40%. These results suggest that

-42-

r-hCG would be more efficient as a therapeutic tool when used in not only one but probably multiple cycles of treatment in order to be fully curative.

5

EXAMPLE 4
Inhibition of Breast Cancer Cells by
hCG and Tamoxifen in vitro

Preliminary *in vitro* experiments were carried out on CG-5 cells, a variant of the MCF-7 cell line (Natoli C. et al., 1983, Breast Cancer Res. Treat. 3:23-32) characterized by a high degree of estrogen responsiveness and an appreciable content of estrogen, androgen, glucocorticoid and progesterone receptors..

15

EXPERIMENTAL PROTOCOL AND PROCEDURES

Cells were routinely cultured in Dulbecco's modified Eagle's medium (DMEM) supplemented with 10% fetal calf serum (FCS) and antibiotics. For cell growth experiments, cells were plated out at the density of 50,000 cells/ml in the medium described above. Twenty-four hours later, the medium was replaced with fresh medium containing 5% charcoal-treated FCS (CH-FCS) plus a fixed concentration (10^{-7} M) of Tamoxifen (TAM) and various concentrations (from 10 to 10,000 IU/ml) of hCG. Medium was renewed every 3 days. In the experiments concerning the effect of hCG and TAM sequentially added to CG-5 cells, cells were plated out at 50,000 cells/ml, as described above, and 24 hours later DMEM was changed with fresh medium containing 10 to 10,000 IU/ml of hCG. For each concentration of hCG, a different number of plates were prepared in order to have a sufficient number of cells to be replaced at the end of the treatment (as hCG has an inhibitory effect itself). After 1 week of exposure to hCG, CG-5 cells were plated in medium

35

-43-

supplemented which 10% FCS and antibiotics, and 24 hours later DMEM was replaced by fresh medium supplemented with 5% CE-FCS and a fixed concentration of TAM (10^{-7} M).

Medium was renewed every 3 days. In all experiments

5 performed cells were counted, after 3 to 6 days, with the use of an hemocytometer.

RESULTS

The simultaneous addition to CG-5 cultures of a
10 fixed concentration of TAM (10^{-7} M) combined with concentrations ranging from 10 to 1,000 IU/ml of hCG, produces an inhibition of cell proliferation which is not related to the dose of hCG but is higher than that induced by TAM alone. At the lowest concentration of
15 hCG, the inhibition of cell proliferation was about 50% with respect to control on the third day from the addition of the two drugs to the culture medium. When cells are treated for 6 days with the combination TAM-hCG, the inhibition of cell proliferation becomes
20 dependent on the dose of hCG and reaches 65% with respect to controls at 1,000 IU/ml of the drug.

CG-5 cells were also pretreated with different concentrations of hCG and subsequently exposed to 10^{-7} M TAM. On the third day after the addition of the
25 antiestrogen to the culture medium, an inhibition of approximately 50% of cell proliferation with respect to control is found in the cells which have received the highest concentration of hCG. On the sixth day after the addition of TAM to the culture medium, the most
30 pronounced inhibition of cell proliferation is obtained in CG-S cells pretreated with the lowest concentration of hCG (about 65% with respect to control) and it remains unmodified in cells pretreated with increasing doses of the drug.

Results are summarized in Figure 7a and 7b, which illustrate graphically the comparison between the different modalities (combined or sequential treatment) used to study the effect of Tamoxifen and hCG on cell growth. Graphs a and b demonstrate the effect of hCG and Tamoxifen added simultaneously (large dot symbol) or sequentially (triangular symbol) to CG-5 cells on the third (a) and sixth (b) day from the addition of the compounds to the culture medium. In the case of sequential administration, cells were pretreated with the hCG concentration indicated in the figure and then exposed to Tamoxifen. The dotted line (---) represents the effect of 10^{-7} M Tamoxifen alone, evaluated in parallel experiments not reported in the text.

Figure 8 shows the effect of hCG alone on the growth of CG-5 cells cultured in identical experimental conditions. In this case the inhibition of cell proliferation is evident after three days of exposure to the hCG starting from the concentration of 100 IU/ml. After six days of treatment with hCG, the inhibitory effect on cell proliferation significantly increases only at the maximum dose of 1000 IU/ml.

The comparison between Figures 7 and 8 clearly shows that such low doses of hCG as 10 IU/ml are efficacious when combined with the anti-estrogen, whereas the same doses are practically ineffective if hCG is used alone. Similar conclusions are reached if the effect of Tamoxifen alone is compared with the combined effect of Tamoxifen with hCG.

The present invention is not limited to the embodiments described and exemplified above, but is capable of variation and modification without departure from the scope of the appended claims.

-45-

We claim:

1. Use of hCG for the manufacture of a medicament for treatment of mammary tumors.

5

2. Use of hCG according to claim 1, for the manufacture of a medicament for the treatment of clinically manifest mammary tumors.

10

3. Use according to claim 2, wherein the clinically manifest mammary tumor is a primary tumor.

4. Use according to any of the preceding claims, wherein the tumor is a non-invasive carcinoma.

15

5. Use according to claim 4, wherein the tumor is ductal carcinoma *in situ* or lobular carcinoma *in situ*.

6. Use according to any of claims 1 to 3, wherein the tumor is an invasive carcinoma.

20

7. Use according to claim 6, wherein the tumor is tubular or lobular invasive carcinoma.

8. Use according to claim 2, wherein the clinically manifest mammary tumor is a metastatic mammary tumor.

25

9. Use of hCG for the manufacture of a medicament for the treatment and/or prevention of mammary tumors in premenopausal or postmenopausal women.

30

-46-

10. Use according to any of the preceding claims, wherein hCG is used as an adjuvant in combination with at least one other cancer therapy.

5 11. Use according to claim 10, wherein the other cancer therapy is surgery or chemotherapy.

10 12. Use according to any of the preceding claims, wherein the treated tumor cells are estrogen receptor-positive.

13. Use according to claim 12, wherein hCG is used in combination with an antiestrogen.

15 14. Use according to claim 13 in which hCG is used simultaneously, sequentially or separately with the antiestrogen.

20 15. Use according to claims 13 or 14, wherein the antiestrogen is Tamoxifen.

25 16. Use according to claim 15, wherein Tamoxifen is administered orally in a daily amount of about 30 milligrams.

17. Use according to any of the preceding claims, wherein hCG is administered in an amount of 100 to 20,000 IU per patient per day.

30 18. Use according to any of the preceding claims, wherein hCG is administered in amount of 50 to 50,000 micrograms per patient per day.

-47-

19. Use according to claim 18, wherein hCG is administered in an amount of 250 to 3,000 micrograms per patient per day.

5 20. Use according to any of the preceding claims, wherein hCG is administered every second day.

21. Use according to any of the preceding claims, wherein hCG is administered three times a week.

10

22. Use according to any of the preceding claims, wherein hCG is administered for several weeks.

15 23. Use according to claim 22, wherein hCG is administered for at least 12 weeks.

24. Use according to any of the preceding claims, wherein hCG is administered subcutaneously.

20 25. Use according to any of the preceding claims, further comprising the use of Type 1 interferon in combination with hCG and antiestrogen.

25 26. Use according to any of the preceding claims, wherein hCG is recombinant hCG.

30 27. Use according to any of claims 1 to 25, wherein hCG is replaced by a protein having the biological activity of hCG and/or a binding activity toward the hCG receptor.

28. Use according to claim 27, wherein the protein is selected from the group consisting of LH,

-48-

recombinant LH, LH fusion molecule, TSH fusion molecules and FSH fusion molecules.

29. A pharmaceutical composition comprising a
5 pharmaceutically active amount of hCG , in the presence of one or more pharmaceutically acceptable excipients, for the treatment of breast cancer.

30. The pharmaceutical composition of claim
10 29, wherein hCG is administered in an amount of 100 to 20,000 IU per patient per day.

31. The pharmaceutical composition of claim 29
15 or 30, wherein hCG is administered in an amount of 50 to 50,000 micrograms per patient per day.

32. The pharmaceutical composition of any of
20 claims 29-31, wherein hCG is administered in an amount of 250 to 3,000 micrograms per patient per day.

33. The pharmaceutical composition of any of
claims 29 to 32, wherein hCG is administered every second day.

25 34. The pharmaceutical composition of any of claims 29 to 32, wherein hCG is administered three times a week.

30 35. The pharmaceutical composition of any of claims 29 to 34, wherein hCG is administered for several weeks.

-49-

36. The pharmaceutical composition of any of claims 29 to 35, wherein hCG is administered for at least 12 weeks.

5 37. The pharmaceutical composition of any of claims 29 to 36, wherein hCG is administered subcutaneously.

10 38. The pharmaceutical composition of any of claims 29 to 37, which is used simultaneously, sequentially or separately with an antiestrogen.

15 39. The pharmaceutical composition of claim 38, wherein the antiestrogen is Tamoxifen.

20 40. The pharmaceutical composition of claim 39, wherein Tamoxifen is administered orally in a daily amount of about 30 milligrams.

25 41. The pharmaceutical composition of any of claims 38 to 40, which is used in combination with a Type 1 interferon.

30 42. The pharmaceutical composition of any of claims 29 to 41, wherein hCG is recombinant hCG.

 43. The pharmaceutical composition of any of claims 29 to 41, wherein hCG is replaced by a protein having the biological activity of hCG and/or a binding activity toward the hCG receptor.

 44. The pharmaceutical composition of claim 43, wherein the protein is selected from the group

-50-

consisting of LH, recombinant LH, LH fusion molecules, FSH fusion molecules and TSH fusion molecules.

45. A method of inhibiting the proliferation
5 of breast cancer cells, comprising administering a host
in need thereof an effective inhibiting amount of hCG.

46. A method of inhibiting the proliferation
of breast cancer cells in postmenopausal women,
10 comprising administering a host in need thereof an
effective inhibiting amount of hCG.

47. A method of inhibiting the proliferation
of metastatic mammary tumor cells, comprising
15 administering a host in need thereof an effective
inhibiting amount of hCG.

48. A method of inhibiting the proliferation
of metastatic mammary tumor cells in postmenopausal
20 women, comprising administering a host in need thereof an
effective inhibiting amount of hCG.

49. The method of any of claims 45 to 48,
comprising additionally administering an effective
25 inhibiting amount of an antiestrogen.

50. The method of claim 49, comprising
additionally administering a Type 1 interferon to the
host.

30

51. The method of any of claims 45 to 50,
wherein hCG is replaced by a protein having the
biological activity of hCG and or a binding activity
toward an hCG receptor.

-51-

52. The method of claim 51, wherein the protein is selected from the group consisting of LH, recombinant LH, LH fusion molecules, FSH fusion molecules and TSH fusion molecules.

5

53. An article of manufacture comprising a container, in which is contained a pharmaceutical composition according to any of claims 29 to 44, and which comprises a label stating the use of the
10 pharmaceutical composition for the treatment of breast cancer.

11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65
66
67
68
69
70
71
72
73
74
75
76
77
78
79
80
81
82
83
84
85
86
87
88
89
90
91
92
93
94
95
96
97
98
99
100
101
102
103
104
105
106
107
108
109
110
111
112
113
114
115
116
117
118
119
120
121
122
123
124
125
126
127
128
129
130
131
132
133
134
135
136
137
138
139
140
141
142
143
144
145
146
147
148
149
150
151
152
153
154
155
156
157
158
159
160
161
162
163
164
165
166
167
168
169
170
171
172
173
174
175
176
177
178
179
180
181
182
183
184
185
186
187
188
189
190
191
192
193
194
195
196
197
198
199
200
201
202
203
204
205
206
207
208
209
210
211
212
213
214
215
216
217
218
219
220
221
222
223
224
225
226
227
228
229
230
231
232
233
234
235
236
237
238
239
240
241
242
243
244
245
246
247
248
249
250
251
252
253
254
255
256
257
258
259
260
261
262
263
264
265
266
267
268
269
270
271
272
273
274
275
276
277
278
279
280
281
282
283
284
285
286
287
288
289
290
291
292
293
294
295
296
297
298
299
300
301
302
303
304
305
306
307
308
309
310
311
312
313
314
315
316
317
318
319
320
321
322
323
324
325
326
327
328
329
330
331
332
333
334
335
336
337
338
339
340
341
342
343
344
345
346
347
348
349
350
351
352
353
354
355
356
357
358
359
360
361
362
363
364
365
366
367
368
369
370
371
372
373
374
375
376
377
378
379
380
381
382
383
384
385
386
387
388
389
390
391
392
393
394
395
396
397
398
399
400
401
402
403
404
405
406
407
408
409
410
411
412
413
414
415
416
417
418
419
420
421
422
423
424
425
426
427
428
429
430
431
432
433
434
435
436
437
438
439
440
441
442
443
444
445
446
447
448
449
450
451
452
453
454
455
456
457
458
459
460
461
462
463
464
465
466
467
468
469
470
471
472
473
474
475
476
477
478
479
480
481
482
483
484
485
486
487
488
489
490
491
492
493
494
495
496
497
498
499
500
501
502
503
504
505
506
507
508
509
510
511
512
513
514
515
516
517
518
519
520
521
522
523
524
525
526
527
528
529
530
531
532
533
534
535
536
537
538
539
540
541
542
543
544
545
546
547
548
549
550
551
552
553
554
555
556
557
558
559
560
561
562
563
564
565
566
567
568
569
570
571
572
573
574
575
576
577
578
579
580
581
582
583
584
585
586
587
588
589
590
591
592
593
594
595
596
597
598
599
600
601
602
603
604
605
606
607
608
609
610
611
612
613
614
615
616
617
618
619
620
621
622
623
624
625
626
627
628
629
630
631
632
633
634
635
636
637
638
639
640
641
642
643
644
645
646
647
648
649
650
651
652
653
654
655
656
657
658
659
660
661
662
663
664
665
666
667
668
669
670
671
672
673
674
675
676
677
678
679
680
681
682
683
684
685
686
687
688
689
690
691
692
693
694
695
696
697
698
699
700
701
702
703
704
705
706
707
708
709
710
711
712
713
714
715
716
717
718
719
720
721
722
723
724
725
726
727
728
729
730
731
732
733
734
735
736
737
738
739
740
741
742
743
744
745
746
747
748
749
750
751
752
753
754
755
756
757
758
759
760
761
762
763
764
765
766
767
768
769
770
771
772
773
774
775
776
777
778
779
780
781
782
783
784
785
786
787
788
789
790
791
792
793
794
795
796
797
798
799
800
801
802
803
804
805
806
807
808
809
810
811
812
813
814
815
816
817
818
819
820
821
822
823
824
825
826
827
828
829
830
831
832
833
834
835
836
837
838
839
840
841
842
843
844
845
846
847
848
849
850
851
852
853
854
855
856
857
858
859
860
861
862
863
864
865
866
867
868
869
870
871
872
873
874
875
876
877
878
879
880
881
882
883
884
885
886
887
888
889
890
891
892
893
894
895
896
897
898
899
900
901
902
903
904
905
906
907
908
909
910
911
912
913
914
915
916
917
918
919
920
921
922
923
924
925
926
927
928
929
930
931
932
933
934
935
936
937
938
939
940
941
942
943
944
945
946
947
948
949
950
951
952
953
954
955
956
957
958
959
960
961
962
963
964
965
966
967
968
969
970
971
972
973
974
975
976
977
978
979
980
981
982
983
984
985
986
987
988
989
990
991
992
993
994
995
996
997
998
999
1000
1001
1002
1003
1004
1005
1006
1007
1008
1009
1010
1011
1012
1013
1014
1015
1016
1017
1018
1019
1020
1021
1022
1023
1024
1025
1026
1027
1028
1029
1030
1031
1032
1033
1034
1035
1036
1037
1038
1039
1040
1041
1042
1043
1044
1045
1046
1047
1048
1049
1050
1051
1052
1053
1054
1055
1056
1057
1058
1059
1060
1061
1062
1063
1064
1065
1066
1067
1068
1069
1070
1071
1072
1073
1074
1075
1076
1077
1078
1079
1080
1081
1082
1083
1084
1085
1086
1087
1088
1089
1090
1091
1092
1093
1094
1095
1096
1097
1098
1099
1100
1101
1102
1103
1104
1105
1106
1107
1108
1109
1110
1111
1112
1113
1114
1115
1116
1117
1118
1119
1120
1121
1122
1123
1124
1125
1126
1127
1128
1129
1130
1131
1132
1133
1134
1135
1136
1137
1138
1139
1140
1141
1142
1143
1144
1145
1146
1147
1148
1149
1150
1151
1152
1153
1154
1155
1156
1157
1158
1159
1160
1161
1162
1163
1164
1165
1166
1167
1168
1169
1170
1171
1172
1173
1174
1175
1176
1177
1178
1179
1180
1181
1182
1183
1184
1185
1186
1187
1188
1189
1190
1191
1192
1193
1194
1195
1196
1197
1198
1199
1200
1201
1202
1203
1204
1205
1206
1207
1208
1209
1210
1211
1212
1213
1214
1215
1216
1217
1218
1219
1220
1221
1222
1223
1224
1225
1226
1227
1228
1229
1230
1231
1232
1233
1234
1235
1236
1237
1238
1239
1240
1241
1242
1243
1244
1245
1246
1247
1248
1249
1250
1251
1252
1253
1254
1255
1256
1257
1258
1259
1260
1261
1262
1263
1264
1265
1266
1267
1268
1269
1270
1271
1272
1273
1274
1275
1276
1277
1278
1279
1280
1281
1282
1283
1284
1285
1286
1287
1288
1289
1290
1291
1292
1293
1294
1295
1296
1297
1298
1299
1300
1301
1302
1303
1304
1305
1306
1307
1308
1309
1310
1311
1312
1313
1314
1315
1316
1317
1318
1319
1320
1321
1322
1323
1324
1325
1326
1327
1328
1329
1330
1331
1332
1333
1334
1335
1336
1337
1338
1339
1340
1341
1342
1343
1344
1345
1346
1347
1348
1349
1350
1351
1352
1353
1354
1355
1356
1357
1358
1359
1360
1361
1362
1363
1364
1365
1366
1367
1368
1369
1370
1371
1372
1373
1374
1375
1376
1377
1378
1379
1380
1381
1382
1383
1384
1385
1386
1387
1388
1389
1390
1391
1392
1393
1394
1395
1396
1397
1398
1399
1400
1401
1402
1403
1404
1405
1406
1407
1408
1409
1410
1411
1412
1413
1414
1415
1416
1417
1418
1419
1420
1421
1422
1423
1424
1425
1426
1427
1428
1429
1430
1431
1432
1433
1434
1435
1436
1437
1438
1439
1440
1441
1442
1443
1444
1445
1446
1447
1448
1449
1450
1451
1452
1453
1454
1455
1456
1457
1458
1459
1460
1461
1462
1463
1464
1465
1466
1467
1468
1469
1470
1471
1472
1473
1474
1475
1476
1477
1478
1479
1480
1481
1482
1483
1484
1485
1486
1487
1488
1489
1490
1491
1492
1493
1494
1495
1496
1497
1498
1499
1500
1501
1502
1503
1504
1505
1506
1507
1508
1509
1510
1511
1512
1513
1514
1515
1516
1517
1518
1519
1520
1521
1522
1523
1524
1525
1526
1527
1528
1529
1530
1531
1532
1533
1534
1535
1536
1537
1538
1539
1540
1541
1542
1543
1544
1545
1546
1547
1548
1549
1550
1551
1552
1553
1554
1555
1556
1557
1558
1559
1560
1561
1562
1563
1564
1565
1566
1567
1568
1569
1570
1571
1572
1573
1574
1575
1576
1577
1578
1579
1580
1581
1582
1583
1584
1585
1586
1587
1588
1589
1590
1591
1592
1593
1594
1595
1596
1597
1598
1599
1600
1601
1602
1603
1604
1605
1606
1607
1608
1609
1610
1611
1612
1613
1614
1615
1616
1617
1618
1619
1620
1621
1622
1623
1624
1625
1626
1627
1628
1629
1630
1631
1632
1633
1634
1635
1636
1637
1638
1639
1640
1641
1642
1643
1644
1645
1646
1647
1648
1649
1650
1651
1652
1653
1654
1655
1656
1657
1658
1659
1660
1661
1662
1663
1664
1665
1666
1667
1668
1669
1670
1671
1672
1673
1674
1675
1676
1677
1678
1679
1680
1681
1682
1683
1684
1685
1686
1687
1688
1689
1690
1691
1692
1693
1694
1695
1696
1697
1698
1699
1700
1701
1702
1703
1704
1705
1706
1707
1708
1709
1710
1711
1712
1713
1714
1715
1716
1717
1718
1719
1720
1721
1722
1723
1724
1725
1726
1727
1728
1729
1730
1731
1732
1733
1734
1735
1736
1737
1738
1739
1740
1741
1742
1743
1744
1745
1746
1747
1748
1749
1750
1751
1752
1753
1754
1755
1756
1757
1758
1759
1760
1761
1762
1763
1764
1765
1766
1767
1768
1769
1770
1771
1772
1773
1774
1775
1776
1777
1778
1779
1780
1781
1782
1783
1784
1785
1786
1787
1788
1789
1790
1791
1792
1793
1794
1795
1796
1797
1798
1799
1800
1801
1802
1803
1804
1805
1806
1807
1808
1809
1810
1811
1812
1813
1814
1815
1816
1817
1818
1819
1820
1821
1822
1823
1824
1825
1826
1827
1828
1829
1830
1831
1832
1833
1834
1835
1836
1837
1838
1839
1840
1841
1842
1843
1844
1845
1846
1847
1848
1849
1850
1851
1852
1853
1854
1855
1856
1857
1858
1859
1860
1861
1862
1863
1864
1865
1866
1867
1868
1869
1870
1871
1872
1873
1874
1875
1876
1877
1878
1879
1880
1881
1882
1883
1884
1885
1886
1887
1888
1889
1890
1891
1892
1893
1894
1895
1896
1897
1898
1899
1900
1901
1902
1903
1904
1905
1906
1907
1908
1909
1910
1911
1912
1913
1914
1915
1916
1917
1918
1919
1920
1921
1922
1923
1924
1925
1926
1927
1928
1929
1930
1931
1932
1933
1934
1935
1936
1937
1938
1939
1940
1941
1942
1943
1944
1945
1946
1947
1948
1949
1950
1951
1952
1953
1954
1955
1956
1957
1958
1959
1960
1961
1962
1963
1964
1965
1966
1967
1968
1969
1970
1971
1972
1973
1974
1975
1976
1977
1978
1979
1980
1981
1982
1983
1984
1985
1986
1987
1988
1989
1990
1991
1992
1993
1994
1995
1996
1997
1998
1999
2000
2001
2002
2003
2004
2005
2006
2007
2008
2009
2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
2026
2027
2028
2029
2030
2031
2032
2033
2034
2035
2036
2037
2038
2039
2040
2041
2042
2043
2044
2045
2046
2047
2048
2049
2050
2051
2052
2053
2054
2055
2056
2057
2058
2059
2060
2061
2062
2063
2064
2065
2066
2067
2068
2069
2070
2071
2072
2073
2074
2075
2076
2077
2078
2079
2080
2081
2082
2083
2084
2085
2086
2087
2088
2089
2090
2091
2092
2093
2094
2095
2096
2097
2098
2099
2100
2101
2102
2103
2104
2105
2106
2107
2108
2109
2110
2111
2112
2113
2114
2115
2116
2117
2118
2119
2120
2121
2122
2123
2124
2125
2126
2127
2128
2129
2130
2131
2132
2133
2134
2135
2136
2137
2138
2139
2140
2141
2142
2143
2144
2145
2146
2147
2148
2149
2150
2151
2152
2153
2154
2155
2156
2157
2158
2159
2160
2161
2162
2163
2164
2165
2166
2167
2168
2169
2170
2171
2172
2173
2174
2175
2176
2177
2178
2179
2180
2181
2182
2183
2184
2185
2186
2187
2188
2189
2190
2191
2192
2193
2194
2195
2196
2197
2198
2199
2




Figure 1




Figure 2




Figure 3




Figure 4

09/868196




Figure 5




Figure 6

09/868196

Fig. 7A





Fig. 7B



hCG CONCENTRATION (IU/ml)

09/868196




Figure 8

COMBINED DECLARATION AND POWER OF ATTORNEY

**(ORIGINAL, DESIGN, NATIONAL STAGE OF PCT, SUPPLEMENTAL, DIVISIONAL,
CONTINUATION, OR C-I-P)**

As a below named inventor, I hereby declare that:

TYPE OF DECLARATION

This declaration is for a national stage of PCT application.

INVENTORSHIP IDENTIFICATION

My residence, post office address and citizenship are as stated below, next to my name. I believe that I am an original, first and joint inventor of the subject matter that is claimed, and for which a patent is sought on the invention entitled:

TITLE OF INVENTION

hCG Therapy for the Treatment of Breast Cancer

SPECIFICATION IDENTIFICATION

The specification was described and claimed in PCT International Application No. PCT/US99/29795 filed on December 15, 1999.

ACKNOWLEDGMENT OF REVIEW OF PAPERS AND DUTY OF CANDOR

I hereby state that I have reviewed and understand the contents of the above-identified specification, including the claims, as amended by any amendment referred to above.

I acknowledge the duty to disclose information, which is material to patentability as defined in 37, Code of Federal Regulations, Section 1.56.

PRIORITY CLAIM (35 U.S.C. Section 119(a)-(d))

I hereby claim foreign priority benefits under Title 35, United States Code, Section 119(a)-(d) of any foreign application(s) for patent or inventor's certificate or of any PCT international application(s) designating at least one country other than the United States of America listed below and have also identified below any foreign application(s) for patent or inventor's certificate or any PCT international application(s) designating at least one country other than the United States of America filed by me on the same subject matter having a filing date before that of the application(s) of which priority is claimed.

Such applications have been filed as follows.

**PRIOR FOREIGN APPLICATION(S) FILED WITHIN 12 MONTHS
(6 MONTHS FOR DESIGN) PRIOR TO THIS APPLICATION
AND ANY PRIORITY CLAIMS UNDER 35 U.S.C. SECTION 119(a)-(d)**

COUNTRY	APPLICATION NUMBER	DATE OF FILING DAY, MONTH, YEAR	PRIORITY CLAIMED UNDER 35 U.S.C. SECTION 119
EP	98123817.3	15 December 1998	yes

POWER OF ATTORNEY

I hereby appoint the following practitioner(s) to prosecute this application and transact all business in the Patent and Trademark Office connected therewith.

APPOINTED PRACTITIONER(S)	REGISTRATION NUMBER(S)
Janet E. Reed	36,252
Scott E. Scioli	47,930
Alfred W. Zaher	42,248
Bruce D. George	43,631

I hereby appoint the practitioner(s) associated with the Customer Number provided below to prosecute this application and to transact all business in the Patent and Trademark Office connected therewith.

SEND CORRESPONDENCE TO

DIRECT TELEPHONE CALLS TO:

Janet E. Reed
215-972-8386

Janet E. Reed
1500 Market Street, 38th Floor
Centre Square West
Philadelphia, PA 19102

DECLARATION

I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code, and that such willful false statements may jeopardize the validity of the application or any patent issued thereon.

SIGNATURE(S)

Irma H. RUSSO

Inventor's signature _____

Date _____

Country of Citizenship US

Residence Rydal, PA

Post Office Address 1211 School Lane, Rydal, PA 19046

Jose RUSSO

Inventor's signature _____


Date _____

Country of Citizenship US

Residence Rydal, PA 19046

Post Office Address 1211 School Lane, Rydal, PA 19046

Giampiero DELUCA

Inventor's signature  _____

Date 12/7/2001 _____

Country of Citizenship ~~CH~~ IT

Residence Geneva CH

Post Office Address Chemin de la Florence 15, Geneva CH-1208 CH

Jaak JANSSENS

Inventor's signature _____

Date _____

Country of Citizenship BE

Residence Hasselt BE

Post Office Address Klein Hilst 5, Hasselt B-3500 BE

COMBINED DECLARATION AND POWER OF ATTORNEY

**(ORIGINAL, DESIGN, NATIONAL STAGE OF PCT, SUPPLEMENTAL, DIVISIONAL,
CONTINUATION, OR C-I-P)**

As a below named inventor, I hereby declare that:

TYPE OF DECLARATION

This declaration is for a national stage of PCT application.

INVENTORSHIP IDENTIFICATION

My residence, post office address and citizenship are as stated below, next to my name. I believe that I am an original, first and joint inventor of the subject matter that is claimed, and for which a patent is sought on the invention entitled:

TITLE OF INVENTION

hCG Therapy for the Treatment of Breast Cancer

SPECIFICATION IDENTIFICATION

The specification was described and claimed in PCT International Application No. PCT/US99/29795 filed on December 15, 1999.

ACKNOWLEDGMENT OF REVIEW OF PAPERS AND DUTY OF CANDOR

I hereby state that I have reviewed and understand the contents of the above-identified specification, including the claims, as amended by any amendment referred to above.

I acknowledge the duty to disclose information, which is material to patentability as defined in 37, Code of Federal Regulations, Section 1.56.

PRIORITY CLAIM (35 U.S.C. Section 119(a)-(d))

I hereby claim foreign priority benefits under Title 35, United States Code, Section 119(a)-(d) of any foreign application(s) for patent or inventor's certificate or of any PCT international application(s) designating at least one country other than the United States of America listed below and have also identified below any foreign application(s) for patent or inventor's certificate or any PCT international application(s) designating at least one country other than the United States of America filed by me on the same subject matter having a filing date before that of the application(s) of which priority is claimed.

Such applications have been filed as follows.

**PRIOR FOREIGN APPLICATION(S) FILED WITHIN 12 MONTHS
(6 MONTHS FOR DESIGN) PRIOR TO THIS APPLICATION
AND ANY PRIORITY CLAIMS UNDER 35 U.S.C. SECTION 119(a)-(d)**

COUNTRY	APPLICATION NUMBER	DATE OF FILING DAY, MONTH, YEAR	PRIORITY CLAIMED UNDER 35 U.S.C. SECTION 119
EP	98123817.3	15 December 1998	yes

POWER OF ATTORNEY

I hereby appoint the following practitioner(s) to prosecute this application and transact all business in the Patent and Trademark Office connected therewith.

APPOINTED PRACTITIONER(S)

REGISTRATION NUMBER(S)

Janet E. Reed	36,252
Scott E. Scioli	47,930
Alfred W. Zaher	42,248
Bruce D. George	43,631

I hereby appoint the practitioner(s) associated with the Customer Number provided below to prosecute this application and to transact all business in the Patent and Trademark Office connected therewith.

SEND CORRESPONDENCE TO

DIRECT TELEPHONE CALLS TO:

Janet E. Reed
215-972-8386

Janet E. Reed
1500 Market Street, 38th Floor
Centre Square West
Philadelphia, PA 19102

DECLARATION

I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code, and that such willful false statements may jeopardize the validity of the application or any patent issued thereon.

SIGNATURE(S)

Irma H. RUSSO

Inventor's signature _____

Date _____

Country of Citizenship US

Residence Rydal, PA

Post Office Address 1211 School Lane, Rydal, PA 19046

Jose RUSSO

Inventor's signature _____

Date _____

Country of Citizenship US

Residence Rydal, PA 19046

Post Office Address 1211 School Lane, Rydal, PA 19046

Giampiero DELUCA

Inventor's signature _____


Date _____

Country of Citizenship ~~CH~~ IT

Residence Geneva CH

Post Office Address Chemin de la Florence 15, Geneva CH-1208 CH

Jaak JANSSENS

Inventor's signature  _____

Date July 11, 2001

Country of Citizenship BE

Residence Hasselt BE

Post Office Address Klein Hilst 5, Hasselt B-3500 BE

COMBINED DECLARATION AND POWER OF ATTORNEY

**(ORIGINAL, DESIGN, NATIONAL STAGE OF PCT, SUPPLEMENTAL, DIVISIONAL,
CONTINUATION, OR C-I-P)**

As a below named inventor, I hereby declare that:

TYPE OF DECLARATION

This declaration is for a national stage of PCT application.

INVENTORSHIP IDENTIFICATION

My residence, post office address and citizenship are as stated below, next to my name. I believe that I am an original, first and joint inventor of the subject matter that is claimed, and for which a patent is sought on the invention entitled:

TITLE OF INVENTION

hCG Therapy for the Treatment of Breast Cancer

SPECIFICATION IDENTIFICATION

The specification was described and claimed in PCT International Application No. PCT/US99/29795 filed on December 15, 1999.

ACKNOWLEDGMENT OF REVIEW OF PAPERS AND DUTY OF CANDOR

I hereby state that I have reviewed and understand the contents of the above-identified specification, including the claims, as amended by any amendment referred to above.

I acknowledge the duty to disclose information, which is material to patentability as defined in 37, Code of Federal Regulations, Section 1.56.

PRIORITY CLAIM (35 U.S.C. Section 119(a)-(d))

I hereby claim foreign priority benefits under Title 35, United States Code, Section 119(a)-(d) of any foreign application(s) for patent or inventor's certificate or of any PCT international application(s) designating at least one country other than the United States of America listed below and have also identified below any foreign application(s) for patent or inventor's certificate or any PCT international application(s) designating at least one country other than the United States of America filed by me on the same subject matter having a filing date before that of the application(s) of which priority is claimed.

Such applications have been filed as follows.

**PRIOR FOREIGN APPLICATION(S) FILED WITHIN 12 MONTHS
(6 MONTHS FOR DESIGN) PRIOR TO THIS APPLICATION
AND ANY PRIORITY CLAIMS UNDER 35 U.S.C. SECTION 119(a)-(d)**

COUNTRY	APPLICATION NUMBER	DATE OF FILING DAY, MONTH, YEAR	PRIORITY CLAIMED UNDER 35 U.S.C. SECTION 119
EP	98123817.3	15 December 1998	yes

POWER OF ATTORNEY

I hereby appoint the following practitioner(s) to prosecute this application and transact all business in the Patent and Trademark Office connected therewith.

4

APPOINTED PRACTITIONER(S)

REGISTRATION NUMBER(S)

Janet E. Reed

36,252

Scott E. Scioli

47,930

Alfred W. Zaher

42,248

Bruce D. George

43,631

I hereby appoint the practitioner(s) associated with the Customer Number provided below to prosecute this application and to transact all business in the Patent and Trademark Office connected therewith.

SEND CORRESPONDENCE TO

DIRECT TELEPHONE CALLS TO:

Janet E. Reed
215-972-8386


Janet E. Reed
1500 Market Street, 38th Floor
Centre Square West
Philadelphia, PA 19102

DECLARATION

I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code, and that such willful false statements may jeopardize the validity of the application or any patent issued thereon.

SIGNATURE(S)

1-00 Irma H. RUSSO

Inventor's signature 


Date 7/25/01

Country of Citizenship US

Residence Rydal, PA PA

Post Office Address 1211 School Lane, Rydal, PA 19046

2-00 Jose RUSSO

Inventor's signature 

Date 7/25/01

Country of Citizenship US

Residence Rydal, PA 19046 PA

Post Office Address 1211 School Lane, Rydal, PA 19046

3-00 Giampiero DELUCA

Inventor's signature _____

Date _____

Country of Citizenship CH

Residence Geneva, CH CHX

Post Office Address Chemin de la Florence 15, Geneva CH-1208 CH

4-00 Jaak JANSSENS

Inventor's signature _____

Date _____

Country of Citizenship BE

Residence Hasselt, BE BEX

Post Office Address Klein Hilst 5, Hasselt B-3500 BE